Public private partnership



This graphic above shows connections between the Gates Foundation, Wellcome Trust, WHO, GAVI and other NGOs and Big Pharma... It contains round about 6500 objects including like Persons, NGOs, Companies, Documents, etc. It also includes more than 7200 links between them.

All information is publicly available.

The following slides presents some selected organizations from this graphic. Cause of the complexity it shows mostly only the first level of connection.

First, you will get some general information about people from government agencies, companies and non-governmental organizations, as well as some important events or groups. Further on in this document you will find a link analysis of these "stakeholders".

The red lines are always payments, but there might be also some black lines are payments as well. Please see link description.

Please make your own opinion and do your own research!

2021-09-12


YGL -
Young
Global
Leaders
BMGF -
Bill & Melinda
Gates
Foundation

Grants from BMGF, Wellcome Trust and OP



Total Grants by Bill & Melinda Gates Foundation (1994-2021) - Top 50 Rows

Sum of AMOUNT COMMITTED	
GRANTEE COUNTRY	Total
United States	43.496.475.796,00
Switzerland	13.106.637.833,00
United Kingdom	2.953.403.252,00
India	1.253.951.882,00
Kenya	1.188.788.307,00
Nigeria	887.239.968,00
Canada	769.413.724,00
South Africa	589.111.107,00
Pakistan	434.859.991,00
Germany	434.000.105,00
France	425.882.803,00
Netherlands	422.472.922,00
Mexico	416.769.415,00
China	395.422.490,00
Australia	336.284.180,00
Korea, Republic of	330.309.122,00
Belgium	309.496.035,00
Japan	290.231.477,00
Italy	261.121.430,00
Saudi Arabia	253.298.091,00
Philippines	220.706.845,00
Bangladesh	175.982.296,00
Congo	134.798.309,00
Norway	130.695.672,00
CÃ´te d'Ivoire	122.098.648,00
Uganda	119.041.383,00
Peru	117.830.886,00
Spain	116.992.589,00
Tanzania, United Republic of	113.471.411,00
Ethiopia	113.140.040,00
Indonesia	113.109.445,00
United Arab Emirates	107.986.151,00
Senegal	103.098.579,00
Singapore	92.601.478,00
Ghana	91.705.501,00
Denmark	68.758.093,00
Thailand	64.054.043,00
Colombia	56.910.013,00
Finland	52.305.171,00
Malaysia	51.596.329,00
Zimbabwe	44.380.389,00
Brazil	44.344.138,00
Viet Nam	34.676.543,00
Sweden	33.880.117,00
Turkey	33.134.337,00
Poland	30.000.094,00
Lithuania	28.852.353,00
Zambia	28.451.800,00
Mauritius	24.092.449,00
Burkina Faso	22.336.886,00
	22.065.038,00
Israel	21.194.906,00
Latvia	20.242.121,00
Chile	19.960.075,00
Rwanda	16.232.978,00

by Devision | By Organization | **by Country** | B

Row Labels	Sum of AMOUNT COMMITTED
GAVI Alliance	4.949.056.550,00
World Health Organization	3.382.840.574,00
The Global Fund to Fight AIDS, Tuberculosis and Malaria	2.998.391.281,00
PATH	2.578.300.627,00
University of Washington Foundation	1.376.710.904,00
United Negro College Fund, Inc.	1.338.312.107,00
The Rotary Foundation of Rotary International	1.285.286.700,00
United States Fund for UNICEF	1.143.667.405,00
The GAVI Campaign	1.137.924.663,00
International Bank for Reconstruction and Development	1.126.822.007,00
Johns Hopkins University	742.059.691,00
MMV Medicines for Malaria Venture	726.814.710,00
Alliance for a Green Revolution in Africa	638.359.987,00
Clinton Health Access Initiative Inc	544.166.541,00
Aeras	513.993.536,00
Foundation for the National Institutes of Health (FNIH)	504.887.034,00
Global Alliance for TB Drug Development Inc	476.021.941,00
New Venture Fund	419.530.642,00
Hispanic Scholarship Fund	419.110.327,00
International AIDS Vaccine Initiative (IAVI)	412.901.894,00
CARE	410.167.727,00
Emory University	387.854.910,00
UNICEF Headquarters	382.653.424,00
United Nations Foundation	363.530.983,00
Centro Internacional de Mejoramiento de Maiz y Trigo	360.843.458,00
Population Services International	352.941.086,00
PATH Vaccine Solutions	343.795.819,00
Duke University	326.168.706,00
World Health Organization Nigeria Country Office	319.456.633,00
University of Manitoba	315.966.351,00
London School of Hygiene and Tropical Medicine	305.031.150,00
Imperial College London	303.563.584,00
Harvard University	298.632.120,00
University of Washington	281.914.723,00
University of California San Francisco	280.217.094,00
Gates Medical Research Institute	276.968.362,00
Family Health International	266.536.106,00
Cornell University	259.876.471,00
International Food Policy Research Institute	256.163.096,00
University of Oxford	254.033.626,00
Islamic Development Bank	246.108.304,00
University of Maryland, Baltimore	245.788.209,00
Save the Children Federation, Inc.	244.266.744,00
International Vaccine Institute	242.583.242,00
World Health Organization Pakistan Country Office	242.356.566,00
Columbia University	240.570.937,00
The One Campaign	237.469.429,00
Global Alliance for Improved Nutrition	235.688.678,00
Fred Hutchinson Cancer Research Center	230.704.021,00
Cambridge University Development Office in the United States Inc (CUDOUS)	229.449.000,00
JSI Research & Training Institute, Inc.	219.074.687,00
FHI Solutions LLC	217.951.412,00
The Carter Center	215.818.664,00
International Development Association	199.732.953,00
FIND	199.240.210,00

by Devision | **By Organization** | BMGF Grants 2021-09-12

Row Labels	Sum of AMOUNT COMMITTED
Global Development	21.314.936.294,00
Global Health	18.397.247.482,00
U.S. Program	9.159.238.029,00
Global Growth & Opportunity	7.567.844.633,00
Global Policy and Advocacy	4.705.588.960,00
Global Development|Global Health	2.952.537.749,00
Executive	1.626.410.176,00
Executive|U.S. Program	1.276.629.387,00
Global Development|Global Policy and Advocacy	827.940.424,00
Global Development|Global Health|Global Policy and Advocacy	520.217.014,00
Global Development|Global Growth & Opportunity	431.529.680,00
Communications|Global Development|Global Health|Global Policy and Advocacy	311.630.758,00
Finance and Resource Planning|Global Development	308.296.430,00
Finance and Resource Planning	264.503.250,00
Gender Equality	263.558.725,00
Global Policy and Advocacy|U.S. Program	238.618.319,00
Global Growth & Opportunity|Global Policy and Advocacy	157.803.334,00
Global Development|Global Growth & Opportunity|Global Health	147.910.332,00
Global Health|Global Policy and Advocacy	111.391.622,00
Gender Equality|Global Development|Global Growth & Opportunity|Global Health|Global Policy and Advocacy	96.408.608,00
Gender Equality|Global Development	91.754.347,00
Foundation Strategy Office	83.796.745,00
Gender Equality|Global Development|Global Health|Global Policy and Advocacy	80.929.595,00
Global Development|Global Growth & Opportunity|Global Health|Global Policy and Advocacy	74.211.934,00
Global Growth & Opportunity|Global Health	60.644.183,00
Executive|Global Health	52.524.087,00
Gender Equality|Global Growth & Opportunity|Global Policy and Advocacy	27.220.184,00
Global Development|Global Growth & Opportunity|Global Policy and Advocacy	25.933.179,00
Finance and Resource Planning|Global Growth & Opportunity	25.000.000,00
Foundation Strategy Office|Global Development|Global Health	24.140.000,00
Gender Equality|Global Growth & Opportunity	15.434.354,00
Gender Equality|Global Policy and Advocacy	11.471.796,00
Executive|Global Development	10.479.708,00
Executive|Gender Equality|Global Development	10.287.499,00
Executive|Global Development|Global Growth & Opportunity	10.000.000,00
Communications|Global Policy and Advocacy	8.847.821,00
Foundation Strategy Office|Global Development|Global Growth & Opportunity|Global Health|Global Policy and Advocacy	8.074.000,00
Foundation Strategy Office|Global Development	7.581.352,00
Executive|Global Development|Global Growth & Opportunity|Global Policy and Advocacy	6.998.115,00
Executive|Global Policy and Advocacy	6.625.000,00
Executive|Gender Equality	6.202.113,00
Gender Equality|Global Development|Global Health	5.684.278,00
Gender Equality|Global Development|Global Policy and Advocacy	5.595.280,00
Communications	5.449.165,00
Gender Equality|Global Development|Global Growth & Opportunity	4.817.705,00
Executive|Global Growth & Opportunity	3.500.013,00
Global Growth & Opportunity|Global Health|Global Policy and Advocacy	2.099.891,00
Global Health|U.S. Program	1.925.000,00
Gender Equality|Global Development|Global Growth & Opportunity|Global Health	1.115.582,00
Global Growth & Opportunity|U.S. Program	733.477,00
Foundation Strategy Office|Gender Equality	569.234,00
Gender Equality|Global Health	566.176,00
Communications|Global Development	199.754,00
Foundation Strategy Office|Global Health	187.672,00
Executive|Global Development|Global Health	152.209,00

by Devision | By Organization | BMGF Grants 2021-09-12

https://www.gatesfoundation.org/about/committed-grants

Overview

Bill & Melinda Gates Foundation, Wellcome Trust, Rockefeller Foundation, World Economic Forum	6
GAVI, CEPI, COVAX, Find, The Global Fund	12
Direct Grants to Swiss Agency for Therapeutic Products, Charite, RKI - Robert Koch Institut, MHRA – Medicines & Healthcare products regulatory Agency and European Commission	23
Direct Grants to World Bank Group and KFW (Link Analysis)	28
Some “Public Websites”	33
Link Analysis	48
Link Analysis – Selected Views	81
IT	96
“EXERCISES”	99
“Meetings”	113
“Gang”	116
Sample of Public Private Partnership - Open Letter to Biden Administration – 3rd August 2021	125
Media	132
Misc	136
“Selected Person”	139

Bill & Melinda Gates Foundation (BMGF)

Direct connections (extract of entire link analysis)



Details you'll find in separate file: CorinaNetwork_GatesFoundationOnlyDirectConnections_2021-09-12.png

https://en.wikipedia.org/wiki/Bill_%26_Melinda_Gates_Foundation
https://www.gatesfoundation.org/
https://www.gatesfoundation.org/about/financials
https://www.gatesfoundation.org/about/committed-grants
https://www.gatesfoundation.org/philanthropypartners
https://www.gatesfoundation.org/goalkeepers/

Bill & Melinda Gates Foundation
Strategic Investment FUND

Portfolio (extract):



1mg Technologies Private Limited
1mg Technologies Private Limited is a digital consumer healthcare platform in India that provides online-to-offline services to help customers access medicines, diagnostics, and tele-consultations. The foundation invested in the Company to accelerate low-cost delivery of high-quality essential medicines and other Read More

Abbott Laboratories
Abbott Laboratories received support from the foundation to make its Panbio COVID-19 Ag Rapid Test available to low- and middle-income countries. Making high-quality, affordable rapid diagnostic tests with results available in 15-20 minutes is critical in the fight to control Read More

Achaogen
Achaogen is focused on R&D and commercialization of antibacterials to combat multi-drug resistant, Gram-negative infections. The foundation's investment is supporting the development of Achaogen's monoclonal antibody ("mAb") discovery platform.
Press Release

Acrobatiq
The foundation invested in Acrobatiq, a leader in adaptive learning solutions, to support the growth of a next-generation adaptive learning, courseware, and analytics program.
Press Release

Adjuvant Global Health Technology Fund
The foundation has committed to further support the Global Health Investment Fund model by investing as an anchor LP in Adjuvant. Adjuvant is a private investment fund focused on late-stage life sciences investments to address global health challenges. The Fund invests Read More

Affinivax
Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine.
News Story

Africa Health Fund
The foundation invested in the Africa Health Fund to provide capital to support new approaches to improving the quality and accessibility of private healthcare across the continent.

African Agricultural Capital Fund
The African Agricultural Capital Fund provides growth capital to companies that boost the productivity and profitability of smallholder farmers in East Africa.
Press Release

African Leadership Fund
The African Leadership Foundation is a U.S. 501(c)(3) organization with a mission to educate Africa's next generation of young leaders. The foundation provided a loan to support the organization's 2020-2021 school year objectives. Investment Date: May 2020

AgBiome
AgBiome is focused on discovery and development of biological and transgenic products for crop protection. AgBiome identifies microbes from a wide variety of sources to harness their natural abilities to help crops resist pests and stresses.
Press Release

1 2 3 ... 8



BioE
Pharmaceutical company Biological E identifies innovative approaches to reduce the cost of vaccine production.
Press Release
News Story

BioNTech
BioNTech is focused on combining ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and other serious diseases. The Foundation is working with BioNTech on developing preclinical vaccines and immunotherapy candidates to prevent HIV and tuberculosis infection as Read More
Press Release

bKash
Through its mobile payments platform, bKash helps to ensure access to a broader range of financial services for the people of Bangladesh.
Press Release
News Story

BloomBoard
Software development company BloomBoard received funding from the foundation to help efforts in improving teachers' instructional practices.
Press Release

Butterfly Network
Butterfly has created the world's first handheld whole body ultrasound system to democratize healthcare and provide global access to medical imaging. The device is critical to the foundation's vision of an ecosystem where hardware, software, data and expertise come together Read More
Press Release
News Story

CHAI (Clinton Health Access Initiative)
The foundation provided a guarantee to CHAI to structure volume guarantees to reduce the price and increase access to life-saving commodities in the developing world.

Charter School Growth Fund Facility Fund
The Charter School Growth Fund provides strategic support to high-performing charter management organizations. Inclusive within its support, CSGF provided subordinated bridge loans to address the short-term financing gap CMOs face during construction.

Charter School Growth Fund Facility Fund III
As a follow-on to the CSGF Facility Fund, the organization created a new fund in 2016, to broaden their lending to include early-stage operators, provide more proactive technical assistance and partner with other key stakeholders to remove barriers to affordable charter facilities and financing.

Civic Builders
Funding from the foundation and New Markets Tax Credits, alongside support from Civic Builders, built new schools in a bankrupt city where facilities assistance was otherwise unavailable.
Case Study

ClinVet
ClinVet specializes in conducting clinical trials to understand and improve veterinary health products. With the help of the foundation, ClinVet was able to construct a new facility in Morocco to expand its capabilities to conduct trials for livestock products.

1 2 3 4 5 ... 8



LumiraDx
LumiraDx develops point-of-care diagnostics solutions on a portable, cloud-connected reader using finger-prick blood samples tested on disposable, microfluidic strips. The company is working to achieve lab-quality performance and health-IT integration at point-of-care settings globally. The foundation invested in the company Read More

Lyndra Therapeutics
Lyndra Therapeutics is developing an orally administered dosage form designed to deliver sustained, steady-state release of one or more drugs for up to a week or longer while temporarily residing in the stomach. The foundation invested in the company to Read More
Press Release

M-KOPA
M-KOPA is a Nairobi-based, off-grid solar energy company, which makes residential power systems affordable and accessible to low-income, off-grid customers through a mobile payment-based lease-to-own model.
Press Release
Case Study

Medical Credit Fund (MCF)
The Medical Credit Fund provides loans and technical assistance to small primary care clinics in Africa. Through the loan fund, MCF expanded its lending and technical assistance across Ghana, Nigeria, Kenya, and Tanzania.
Press Release

Merck
The foundation partnered with private and public organizations make Implanon NXT®, a single rod, long-acting, reversible contraceptive implant, available in the world's poorest countries at a more than 50 percent price reduction.
Press Release
Case Study

Mylan Dolutegravir
Mylan Laboratories, along with Aurobindo Pharma, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price.
Press Release
News Story

OraSure
The foundation invested in OraSure to secure a reduced price for the saliva-based HIV self-test OraQuick.
Press Release
News Story

Owl Ventures
Owl Ventures is a venture investment fund that leads Series A/B investments in US K-12 education technology companies.

PAHO
The Pan American Health Organization (PAHO) is an international public health agency working to improve health and living standards in America.

Pfizer
The foundation invested in Pfizer to expand access to the pharmaceutical company's all-in-one injectable contraceptive, Sayana, giving women in the developing world an affordable option.

1 ... 4 5 6 7 8

https://sif.gatesfoundation.org/portfolio/

Wellcome Trust

Direct connections (extract of entire link analysis)



https://wellcome.org
https://en.wikipedia.org/wiki/Wellcome_Trust

Rockefeller Foundation

Here you can see only a small excerpt of the Rockefeller Foundation. The Rockfeller Foundation's connections are actually much more far-reaching. No connections to other Rockefeller NGOs, such as Rockefeller Philanthropy Advisors, Rockefeller Brothers Fund, etc. are shown here.



https://www.rockefellerfoundation.org/about-us/board-of-trustees/
https://www.rockefellerfoundation.org/grants/
https://en.wikipedia.org/wiki/Rockefeller_Foundation
http://www.nommeraadio.ee/meedia/pdf/RRS/Rockefeller%20Foundation.pdf

World Economic Forum (WEF)

“The World Economic Forum
The World Economic Forum is the International Organization for Public-Private Cooperation.
The Forum engages the foremost political, business, cultural and other leaders of society to shape global, regional and industry agendas.
It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial and not tied to any special interests. The Forum strives in all its efforts to demonstrate entrepreneurship in the global public interest while upholding the highest standards of governance. Moral and intellectual integrity is at the heart of everything it does.
Our activities are shaped by a unique institutional culture founded on the stakeholder theory, which asserts that an organization is accountable to all parts of society. The institution carefully blends and balances the best of many kinds of organizations, from both the public and private sectors, international organizations and academic institutions.
We believe that progress happens by bringing together people from all walks of life who have the drive and the influence to make positive change.
Read the latest Annual Report here. Find out about our Foundation Regulations and Statutes.”

https://www.weforum.org/about/world-economic-forum

“World Economic Forum Partners are leading global companies developing solutions to the world’s greatest challenges. They are the driving force behind the Forum’s programmes. Our Partners engage in Forum Platforms to shape the future, accessing networks and experts to ensure strategic decision-making on the most pressing world issues.”

https://www.weforum.org/partners



https://intelligence.weforum.org/topics/a1G0X000006O6EHUA0?tab=publications

World Economic Forum (WEF)

Direct connections
(extract of entire link analysis)



GAVI, officially **Gavi, the Vaccine Alliance**

(previously the **GAVI Alliance**, and before that the **Global Alliance for Vaccines and Immunization**)

"GAVI facilitates vaccinations in developing countries by working with donor governments, the World Health Organization,[4] UNICEF,[5] the World Bank,[6] the vaccine industry in both industrialised and developing countries, research and technical agencies, civil society, the Bill & Melinda Gates Foundation[7] and other private philanthropists. GAVI has observer status at the World Health Assembly."

https://en.wikipedia.org/wiki/GAVI

„Die Impfallianz Gavi wurde am 29. Januar 2000 am **Weltwirtschaftsforum (WEF – World Economic Forum) in Davos** ins Leben gerufen. "

https://www.savethechildren.de/news/20-jahre-im-einsatz-fuer-kinder-die-impfallianz-gavi/

https://www.gavi.org/our-alliance/about

GAVI - Direct connections (extract of entire link analysis)



GAVI has full immunity in Switzerland

Abkommen

zwischen dem **Schweizerischen Bundesrat** und **GAVI Alliance** (Global Alliance for Vaccines and Immunization) zur Regelung des rechtlichen Statuts von GAVI Alliance in der Schweiz

https://www.fedlex.admin.ch/eli/cc/2009/541/de

(Stand am 1. Januar 2009)

[1] Der Originaltext findet sich unter der gleichen Nummer in der französischen Ausgabe dieser Sammlung.

Der Schweizerische Bundesrat

einerseits

und
GAVI Alliance (Global Alliance for Vaccines and Immunization)

anderseits,

in dem Wunsche, ihre Beziehungen in einem Sitzabkommen zu regeln,

sind wie folgt übereingekommen:

I. Statut, Vorrechte und Immunitäten von GAVI Alliance

Art. 1 Persönlichkeit und Rechtsfähigkeit

Der Schweizerische Bundesrat anerkennt die internationale Rechtspersönlichkeit und die Rechtsfähigkeit von GAVI Alliance in der Schweiz.

Art. 2 Unabhängigkeit und Handlungsfreiheit

1. Der Schweizerische Bundesrat garantiert GAVI Alliance Unabhängigkeit und Handlungsfreiheit.

2. Er gewährt ihr die uneingeschränkte Versammlungsfreiheit, einschliesslich der Rede-, Beschluss- und Publikationsfreiheit, auf dem Hoheitsgebiet der Schweiz.

Art. 3 Unverletzbarkeit der Räumlichkeiten

Die Gebäude oder Gebäudeteile und das anliegende Gelände, die von GAVI Alliance für ihre eigenen Zwecke benützt werden, sind ungeachtet der herrschenden Eigentumsverhältnisse unverletzbar. Kein Vertreter schweizerischer Behörden darf sie ohne ausdrückliche Zustimmung des Exekutivdirektors von GAVI Alliance oder der von ihm bezeichneten Person betreten.

Art. 4 Unverletzbarkeit der Archive

Die Archive von GAVI Alliance und alle ihr gehörenden oder in ihrem Besitz befindlichen Dokumente und Datenträger ganz allgemein sind jederzeit und überall unverletzbar.

Art. 5 Immunität von der Gerichtsbarkeit und der Vollstreckung

1. Im Rahmen ihrer Tätigkeit geniesst GAVI Alliance Immunität von der Gerichtsbarkeit und der Vollstreckung, ausser:

   a) wenn diese Befreiung im Einzelfall vom Exekutivdirektor oder durch die von ihm bezeichnete Person ausdrücklich aufgehoben worden ist;
   b) im Falle einer gegen GAVI Alliance angestrengten zivilrechtlichen Haftungsklage wegen eines Schadens, der durch ein GAVI Alliance gehörendes oder auf ihre Rechnung betriebenes Kraftfahrzeug verursacht wurde;
   c) im Falle einer durch richterlichen Entscheid angeordneten Beschlagnahme von Gehältern, Löhnen und anderen Bezügen, welche GAVI Alliance einem ihrer Beamten schuldet;
   d) im Falle einer Widerklage, die in unmittelbarem Zusammenhang mit einer von GAVI Alliance erhobenen Hauptklage steht; und
   e) im Falle der Vollstreckung einer schiedsrichterlichen Entscheidung, welche in Anwendung von Artikel 29 dieses Abkommens gefällt wurde.

2. Die Gebäude oder Gebäudeteile, das anliegende Gelände sowie die Vermögenswerte, die sich im Eigentum von GAVI Alliance befinden oder von ihr zu ihren Zwecken benutzt werden, sind unabhängig von ihrem Standort und ihrem Besitzer befreit von:

   a) jeglicher Form von Requisition, Beschlagnahme oder Enteignung;
   b) jeglicher Form von Zwangsvollstreckung, anderen behördlichen Zwangsmassnahmen oder Massnahmen, die einem Urteil vorausgehen, mit Ausnahme der in Absatz 1 vorgesehenen Fälle.

Art. 6 Veröffentlichungen und Mitteilungen

CEPI - Coalition for Epidemic Preparedness Innovations

CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum.

To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome.
https://cepi.net/about/whoweare/

CEPI - Coalition for Epidemic Preparedness Innovations



CEPI - Coalition for Epidemic Preparedness Innovations

This link analysis shows direct path of people are shown in previous graph.

Please have a look at separate file:

Corina_Network_CEPI_PeopleAndTheirDirectPath_2021-09-12.png



FIND

“FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world.
We connect countries and communities, funders, decisionmakers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems.
We are working to save 1 million lives through accessible, quality diagnosis, and save US$1 billion in healthcare costs to patients and health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic”

https://www.finddx.org/about/

https://www.finddx.org/
https://dndi.org/press-releases/2010/international-status-granted/
https://en.wikipedia.org/wiki/Foundation_for_Innovative_New_Diagnostics

FIND


David L. Heymann
BMGF - Bill & Melinda Gates Fou...
Financed (Alliance Partner)
Financed
Finances via WHO
Michael Watson
Georg F Gao
WHO - World Health Organization
Donor
Partner
UKAID
BMBF - Bundesministerium für Bi...
CEPI Coalition for Epidemic Pre...
The Global Fund
Mark Kessel
Daniel Camus
CDC - Centers for Disease Contr...
USAID
Ilona Kickbusch
Marcel Tanner
EDCTP - European & Developing C...
SHOBANA KAMINENI
Sergio Carmona
UnitAid
CARLOS MOREL
ANDREW JACK
KfW Entwicklungsbank
SHEILA D. TLOU
Donor
Board Member
Finance 40 Mio - 5 Years
FIND
CARB-X Global Accelerators
CARB-X

COVAX / ACT-A

COVAX

With a fast-moving pandemic, no one is safe, unless everyone is safe

COVAX is co-led by CEPI, Gavi and WHO, alongside key delivery partner UNICEF. In the Americas, the PAHO Revolving Fund is the recognized procurement agent for COVAX.

CEPI Gavi unicef World Health Organization



https://www.who.int/initiatives/act-accelerator/covax
https://www.gavi.org/vaccineswork/covax-explained
https://en.wikipedia.org/wiki/COVAX

2,2 Milliarden Euro für Impfungen, Diagnostik und Medikamente

Die Pandemie kann nur besiegt werden, wenn sie weltweit unter Kontrolle gebracht wird: Deutschland hat sich deshalb schon früh für eine gemeinsame und solidarische Antwort auf die Pandemie stark gemacht. Nach dem Grundsatz „Niemand ist sicher, bis alle sicher sind“ hat Deutschland im vergangenen Jahr den Koordinierungsmechanismus Access to Covid-19 Tools Accelerator (ACT-A) mitgegründet. Als derzeit zweitgrößter Geber von ACT-A hat Deutschland bislang 2,2 Milliarden Euro zur Verfügung gestellt. Der Großteil der Unterstützung geht an die internationale Impfstoffplattform COVAX, ein Teil wird auch für Diagnostik und Medikamente gegen die Krankheit verwendet. Bis Anfang August wurden dadurch bereits 138 Staaten mit insgesamt über 200 Millionen Dosen der Impfstoffe von AstraZeneca, Johnson & Johnson, Moderna und BioNTech versorgt.

Auszug aus https://www.auswaertiges-amt.de/de/aussenpolitik/themen/gesundheit/covax/2395748 vom 26.08.2021

Weiterführende Links:
https://www.who.int/initiatives/act-accelerator
https://www.gavi.org/covax-facility

The Global Fund

„Der **Globale Fonds zur Bekämpfung von AIDS, Tuberkulose und Malaria** (englisch **The Global Fund to Fight AIDS, Tuberculosis and Malaria,** kurz GFATM) mit Sitz in Genf, Schweiz, ist ein Finanzierungsinstrument zur Bekämpfung der drei großen Infektionskrankheiten AIDS, Tuberkulose und Malaria. Der weltweit in mehr als 100 Ländern tätige Fonds ist eines der wichtigsten Instrumente zur Bekämpfung dieser Krankheiten."

„Der Fonds wurde im Jahr 2002 gegründet, nachdem sich die G8-Staaten auf ihrem Treffen in Genua 2001 darauf verständigt hatten, die Finanzierung des weltweiten Kampfes gegen die drei schweren Infektionskrankheiten AIDS, Tuberkulose und Malaria zu verstärken. Schon ein Jahr zuvor forderte der ehemalige UN-Generalsekretär Kofi Annan die Einrichtung eines solchen Fonds[2].
Der Fonds dient der Finanzierung nationaler Maßnahmen gegen die drei Krankheiten einschließlich der Stärkung von Gesundheitssystemen. Er fördert zudem die Eigenverantwortung der Regierungen, die Mitwirkung der Zivilgesellschaft und des privaten Sektors sowie wirkungs- und genderorientierte Maßnahmen gegen Aids, Tuberkulose und Malaria.
Der ehemalige Leiter des US-AIDS-Programms PEPFAR (President's Emergency Plan for AIDS Relief), Mark Dybul, wurde im Jahre 2012 zum Leiter des Globalen Fonds gewählt. Er hatte dieses Amt bis Mai 2017 inne. Mark Dybul gilt in Fachkreisen als Visionär im Bereich globaler Gesundheit und hatte maßgeblich an der Gründung und Durchführung des Notfallplans des US-Präsidenten für AIDS-Bekämpfung (PEPFAR) beigetragen. Als Arzt mit dem Schwerpunkt Immunologie wurde er als Mediziner, Wissenschaftler und strategisch denkender Verwalter zum ausgewiesenen HIV- und AIDS-Experten. Nach dem Abschied von Mark Dybul leitete Marijke Wijnroks vorübergehend die Organisation. Seit März 2018 ist Peter Sands Direktor des GFATM."

„Deutschland und der Globale Fonds
Als viertgrößter Geber (nach den USA, Frankreich und Großbritannien) leistet Deutschland einen bedeutenden Beitrag zur weltweiten Bekämpfung von AIDS, Tuberkulose und Malaria.[13]
Zudem spielt das Land als Mitglied des Verwaltungsrats eine entscheidende Rolle dabei, den globalen Fonds bei der Umstrukturierung und Straffung von dessen Betriebsabläufen zu unterstützen, damit die Investitionen der Organisation durchdacht getätigt werden und auf maximale Wirkung ausgerichtet sind.
Außerdem hat der Fonds ein neues Finanzierungsmodell eingeführt. Durch das neue Finanzierungsmodell wird eine stärkere Verantwortung der Länder für Projekte gefördert. Zudem wirkt das neue Finanzierungsmodell als Anreiz für politischen Dialog mit den Programmdurchführungsländern und zielt gleichzeitig auf die Berücksichtigung von Themen der Gleichberechtigung von Männern und Frauen sowie der sexuellen und reproduktiven Gesundheit und von Menschenrechtsbelangen ab. Der Landesdialog als Schlüsselelement des neuen Finanzierungsmodells bietet außerdem neue Chancen für das Engagement aller Partner, auch aus der Zivilgesellschaft und der freien Wirtschaft.
Neben diesen Beiträgen ist Deutschland auch einer der führenden Schirmherren des Programms Debt2Health des Globalen Fonds, das weltweit zu einem erheblichen Anstieg der Förderung von Programmen des Globalen Fonds geführt hat. Im Rahmen dieser Initiative hat Deutschland in Ländern wie Côte d'Ivoire, Indonesien, Pakistan und Ägypten einen Schuldenschnitt vorgenommen."

https://de.wikipedia.org/wiki/Global_Fund
https://en.wikipedia.org/wiki/The_Global_Fund_to_Fight_AIDS,_Tuberculosis_and_Malaria
https://www.theglobalfund.org/en/overview/
https://www.theglobalfund.org/en/
https://www.theglobalfund.org/en/board/
https://www.theglobalfund.org/en/private-ngo-partners/resource-mobilization/bill-melinda-gates-foundation/

The Global Fund



Direct grants from Bill & Melinda Gates Foundation (BMGF) to

- Swiss Agency for Therapeutic Products, Switzerland
- Charite, Germany
- RKI - Robert Koch Institut, Germany
- MHRA – Medicines & Healthcare products regulatory Agency, United Kingdom

- European Commission

3 OF 3 FOR "SWISS AGENCY"

Date Last Updated: ***8.23.2021***

Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Therapeutic Products	Global Health	FEBRUARY 2020	GLOBAL +1	$900,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Development of Solutions to Improve Global Health	46	Berne, Switzerland	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Therapeutic Products	Global Health	DECEMBER 2015	GLOBAL +1	$1,332,000
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Development of Solutions to Improve Global Health	67	Berne, Switzerland	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Swiss Agency for Development and Cooperation	Global Growth & Opportunity	SEPTEMBER 2010	GLOBAL +2	$453,381
	GRANT TOPIC	DURATION (MONTHS)	GRANTEE LOCATION	
	Water, Sanitation and Hygiene	48	Bern, Switzerland	

Show 10

https://www.gatesfoundation.org/about/committed-grants?q=Swiss%20Agency

https://www.swissmedic.ch/swissmedic/de/home/ueber-uns/internationale-zusammenarbeit/multilaterale-zusammenarbeit-mit-internationalen-organisationen-/bill-and-melinda-gates-foundation.html

3 OF 3 FOR "CHARITÉ"

Date Last Updated: ***8.23.2021***

Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Charité - Universitätsmedizin Berlin	Global Health	MARCH 2020	GLOBAL	$249,550
	GRANT TOPIC: Support Innovative Technology Solutions	DURATION (MONTHS): 40	GRANTEE LOCATION: Berlin, Germany	
Charité - Universitätsmedizin Berlin	Global Health	DECEMBER 2019	GLOBAL	$86,181
	GRANT TOPIC: Pneumonia	DURATION (MONTHS): 4	GRANTEE LOCATION: Berlin, Germany	
Charité - Universitätsmedizin Berlin	Global Policy and Advocacy	OCTOBER 2018	GLOBAL	$549,999
	GRANT TOPIC: Global Health and Development Public Awareness and Analysis	DURATION (MONTHS): 14	GRANTEE LOCATION: Berlin, Germany	

https://www.gatesfoundation.org/about/committed-grants?q=Charit%C3%A9

1 OF 1 FOR "ROBERT KOCH"

Date Last Updated: ***8.23.2021***

Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Robert Koch Institute	Global Health	NOVEMBER 2019	GLOBAL	$253,000
	GRANT TOPIC: Vaccine Development	DURATION (MONTHS): 59	GRANTEE LOCATION: Berlin, Berlin, Germany	

Show 10

https://www.gatesfoundation.org/about/committed-grants?q=robert%20koch

Press release

MHRA awarded over £980,000 for collaboration with the Bill and Melinda Gates Foundation and the World Health Organisation

MHRA today announced a partnership worth over £980,000 to improve the safety monitoring of medicines in low and middle-income countries.

From: Medicines and Healthcare products Regulatory Agency
Published 15 December 2017

Medicines & Healthcare products Regulatory Agency

We are delighted to announce a new partnership with the Bill & Melinda Gates Foundation and the World Health Organisation that aims to extensively improve the safety monitoring of medicines in low and middle-income countries (LMIC).

New medicines and vaccines, for diseases such as malaria and HIV, may be introduced for the first time in LMIC's where there are weak or no regulatory

Related content

Report of the Commission on Human Medicines Expert Working Group on Optimising Data on Medicines used During Pregnancy

Report of the Commission on Human Medicines' Expert Working Group on Hormone Pregnancy Tests

Safer Medicines in Pregnancy and Breastfeeding Consortium

Epilepsy medicines and pregnancy

Brexit

Check what you need to do

https://www.gov.uk/government/news/mhra-awarded-over-980000-for-collaboration-with-the-bill-and-melinda-gates-foundation-and-the-world-health-organisation

Press release

MHRA and the Bill & Melinda Gates Foundation to look at the safer, effective use of medicines during pregnancy

MHRA and the Bill & Melinda Gates Foundation have begun new research on medicine use which could impact the health of pregnant women around the world.

From: Medicines and Healthcare products Regulatory Agency
Published 17 September 2019

In advance of World Patient Safety Day (17 September), MHRA specialists, as part of a broader programme of work, have begun developing ground-breaking research to support the safer use of medicine during pregnancy.

A $360,000 grant over two years from the Bill & Melinda Gates Foundation (approximately £292,000), will support the MHRA's research, to help predict the need for adjusting a medicine's dose during different trimesters of pregnancy. This will ensure effective use, which is vitally important for the health of mother and baby.

Worldwide, data in this area remain limited, and new insights could potentially impact the health of pregnant women around the world. This would also give obstetricians further clarity on the optimal dose of a

Brexit

Check what you need to do

https://www.gov.uk/government/news/mhra-and-the-bill-melinda-gates-foundation-to-look-at-the-safer-effective-use-of-medicines-during-pregnancy

Date Last Updated: ***9.6.2021***

Committed Grants; sort by Date Descending

Date Descending

GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
European Commission	Global Development	MARCH 2020	GLOBAL +1	$500,000
	GRANT TOPIC: Nutrition	DURATION (MONTHS): 17	GRANTEE LOCATION: Brussels, Belgium	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
European Commission	Global Health	MARCH 2019	GLOBAL +1	$45,178,000
	GRANT TOPIC: Development of Solutions to Improve Global Health	DURATION (MONTHS): 238	GRANTEE LOCATION: Brussels, Belgium	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
European Centre for Development Policy Management	Global Policy and Advocacy	MARCH 2017	GLOBAL	$399,982
	GRANT TOPIC: Global Health and Development Public Awareness and Analysis	DURATION (MONTHS): 25	GRANTEE LOCATION: Maastricht, Netherlands	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
European Commission	Global Development	FEBRUARY 2016	GLOBAL +2	$500,000
	GRANT TOPIC: Nutrition	DURATION (MONTHS): 22	GRANTEE LOCATION: Brussels, Belgium	
GRANTEE	DIVISION	DATE	REGION SERVED	COMMITTED AMOUNT
Imperial College London	Global Growth & Opportunity	SEPTEMBER 2010	GLOBAL +1	$2,692,835
	GRANT TOPIC: Agricultural Development	DURATION (MONTHS): 40	GRANTEE LOCATION: London, United Kingdom	

https://www.gatesfoundation.org/about/committed-grants?q=european%20commission

World Bank - Partners

https://www.worldbank.org/en/topic/financialinclusion/overview#4

https://www.globalfinancingfacility.org/sites/gff_new/files/documents/GFF-IG1-2_Participant%20List_%209_25.pdf

CONTEXT | STRATEGY | RESULTS | PARTNERS

The World Bank Group works globally with standard-setting bodies to develop guidelines, standards and good practices. We also work with the G20 to develop guidance for regulators and policymakers and to catalyze new actions in support of financial inclusion. We are also an implementing partner for the G20 Global Partnership for Financial Inclusion (GPFI).

We also work closely with a number organizations and donor partners to advance financial inclusion, including Alliance for Financial Inclusion (AFI), AusAid, the Bill and Melinda Gates Foundation, DFID, Financial Sector Development Trusts, GIZ, the Ministry of Foreign Affairs of the Netherlands, the OECD, SECO, UNCDF, UNCITRAL, UNSGSA, USAID, and regional development banks.

The Ministry of Foreign Affairs of the Netherlands and the Bill and Melinda Gates Foundation provide the funding for the Financial Inclusion Support Framework (FISF), while SECO provides funding for the Consumer Protection and Financial Literacy (CPFL) program, and DFID provides funding for the Harnessing Innovation for Financial Inclusion (HiFi) program.

World Bank


Tim Evans
Ngozi Okonjo-Iweala
Sheila Redzepi
Peter Sands
Jeffrey Sachs
Resolve to Save Lives
Mamta Murthi
Former Senior Director of the Health, Nutrition and Population Global Practice
https://blogs.worldbank.org/team/tim-evans
worked for
Previous Board Member
Worked for
Vice-President for External and Corporate Affairs
World Bank
Present Board Member
Founding Partner
belongs to
Name
IFC Internation Finance Corpora...
Bank Information Center (BIC)
International Finance Organiz...
CEPI
CEPI - Coalition for Epidemic Pre...
GAVI
Jeremy Veillard
GPMB
Apolitical
MMV - Medicines for Malaria Ven...
Results for Develop...
TDR, the Special Programme for ...
Program Manager, PHCPI & Strategic Policy Adviser to Auth...
Senior Director
IBRD - International Bank for R...
Global Citizen
IDA - International Develop...
MSI Reproductive Choices / Mari...
World Bank Blog
UHC2030
IFFIM - International Finance
PHCPI - Primary Health Care Per...

IFC Internation Finance Corporation (World Bank)



GFF – Global Financing Facility (World Bank)




KfW
Bundesregierung
Bill & Melinda Gates Foundation
Staatseigene Förderbank
KFW
kfw Entwicklungsbank
Donor
Adjuvant Capital
CureVac AG
PharmAccess Foundation
FIND

Some “Public Websites”

Please look at the people and organizations.

You’ll find some of them later in several link analysis.

Mai 2017 / August 2018

Four new members complete the International Advisory Board on Global Health

https://www.bundesgesundheitsministerium.de/english-version/press/2018/international-advisory-board.html

Meeting in July with some members of the IAB and two Secretary of States (from left to right: Farrar, Roses, Hacker, Kickbusch, Secretary of State Stroppe, Nishtar, Elias, Schneider, Secretary of State Flachsbarth, Benn)

The Advisory Board consists of ten German and international experts. Six members of the International Advisory Board on Global Health have already been appointed by the Federal Ministry of Health in August 2017. Another four were appointed as members in May 2018. The Board now includes experts from different regions and stakeholder groups that have extensive expertise on various global health topics.

Members of the International Advisory Board on Global Health

- Prof Dr Ilona Kickbusch, Director of the Global Health Centre at the Graduate Institute of International and Development Studies, Geneva (Chair of the board)
- Prof Dr Christian Drosten, Chair of the Institute of Virology at the Charité Berlin
- Dr Christopher Elias, President of the Global Development Program, Bill & Melinda Gates Foundation
- Dr Jeremy Farrar, Director of the Wellcome Trust
- Prof Dr Jörg Hacker, President of the German National Academy of Sciences Leopoldina
- Dr Matshidiso Rebecca Moeti, WHO Regional Director for Afrika
- Dr Mirta Roses Periago, former Director of the Pan American Health Organization
- Dr Sania Nishtar, President of Heartfile
- Dr Gisela Schneider, Director of the German Institute for Medical Mission
- Dr Christoph Benn, Director for External Relations of the Global Fund to Fight AIDS,

Mai 2018

WHO Global Preparedness Monitoring Board

The Global Preparedness Monitoring Board is a joint arm of the WHO and the World Bank.

Created in response to recommendations by the UN Secretary General's Global Health Crises Task Force in 2017, the GPMB was co-convened by the World Health Organization and the World Bank Group and formally launched in May 2018

https://apps.who.int/gpmb/


Co-chairs
Board Members
Co-conveners
Dr Victor Dzau
President of the US National Academy of Medicine, USA
Dr Chris Elias
President, Global Development Program, Bill & Melinda Gates Foundation, USA
Sir Jeremy Farrar
Director, Wellcome Trust, UK
Dr Anthony S Fauci
Director, National Institute of Allergy and Infectious Diseases, USA
Ms Henrietta Fore
Executive Director, UNICEF
Dr George F. Gao
Director-General, Chinese Center for Disease Control and Prevention, People's Republic of China
H.E. Sigrid Kaag
Minister for Foreign Trade and Development Cooperation, The Netherlands
Prof Ilona Kickbusch
Chair of the International Advisory Board of the Global Health Centre at the Graduate Institute of International
Dr Ngamije M. Daniel
Minister of Health
Republic of Rwanda

8. Mai 2019

CDU Veranstaltung – Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen

https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten


CDU CSU
Themen
Plenum
Fraktion
Abgeordnete
Veranstaltungen
Presse
Publikationen
Mediathek
Alle Referenten
Hermann Gröhe
Stellvertretender Vorsitzender der CDU/CSU-Bundestagsfraktion | Beauftragter für Kirchen und Religionsgemeinschaften
Ralph Brinkhaus
Vorsitzender der CDU/CSU-Fraktion im Deutschen Bundestag
Dr. Angela Merkel
Bundeskanzlerin der Bundesrepublik Deutschland
Prof. Ilona Kickbusch PHD
Graduate Institute of International and Development Studies Geneva
Letzte Veranstaltung 08.05.2019 - 14:30
Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen
Dr. Tedros Adhanom Ghebreyesus
Generaldirektor der Weltgesundheitsorganisation
Letzte Veranstaltung 08.05.2019 - 14:30
Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen
Prof. Dr. Christian Drosten
Institut für Virologie Charité – Universitätsmedizin Berlin
Letzte Veranstaltung 08.05.2019 - 14:30
Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen
Prof. Dr. Clarissa Prazeres da Costa
Institut für Medizinische Mikrobiologie, Immunologie und Hygiene | Technische Universität München
Letzte Veranstaltung 08.05.2019 - 14:30
Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen
Joe Cerrell
Geschäftsführender Direktor Globale Politik | Bill and Melinda Gates Foundation
Letzte Veranstaltung 08.05.2019 - 14:30
Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen
Prof. Jeremy Farrar
Direktor Wellcome Trust
Letzte Veranstaltung 08.05.2019 - 14:30
Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen
Dr. Georg Kippels
Jens Spahn
Bundesminister für Gesundheit

Global Health Hub Germany

The Global Health Hub Germany is a network that aims to bring together all actors interested in Global Health. The Hub wants to promote exchange, initiate new partnerships, support cooperation and innovative approaches - across sectors and stakeholder groups.
Membership is open to both individuals and organizations from all areas and sectors involved in Global Health - stakeholders from science, the private sector, civil society and politics, as well as from the health, environment, climate, food, agriculture, education and research sectors.

The Hub was inaugurated by Minister of Health Jens Spahn in February 2019 with a kick-off event at the Federal Ministry of Health. The Ministry of Health is providing funding for three years (2019-2021) for the set-up of the Hub and the establishment of the office.
Since the kick-off, the number of members has increased continuously: more than 1150 individuals and organizations have by now registered to make new contacts, exchange views on current issues and work together.

To promote cooperation and exchange, the Hub offers various possibilities and formats:

- Members can collaborate in cross-sectoral and cross-actor working groups on issues of their choice. Approximately 20 working groups have already been established on topics such as "Universal health coverage through digital technology", "Climate and Health" or "Global Mental Health". In the "Virtual Working Space", in the members only area of the website, interested members can join the already existing working groups to collaborate and discuss. Your topic is not included yet? No problem, you can suggest a new working group and search for fellow members who are interested in working on the same topic.
- With different types of events the Hub promotes regular exchange between members. In addition to face-to-face events, such as the annual Global Health Talk, webinars are held regularly to discuss current topics or present the work of the members.
- All registered members can be found in the member database in the members only area of the website. There you can search for experts on specific topics or from specific stakeholder groups. You can send networking requests, exchange views and discuss via the website by using the chat feature.
- In an interactive forum all members can informally exchange information, ask questions or give advice.

https://www.globalhealthhub.de/index.php/en/content/about-hub


ABOUT
EVENTS CALENDAR
NEWS
WORKING GROUPS
LOGIN
REGISTER
EN
DE
Steering Committee
The Steering Committee is responsible for the strategic planning, further development and direction of the Hub.
The Steering Committee consists of 16 representatives who on a parity basis represent the stakeholder groups science, private sector, civil society and youth as well as think tanks, foundations, the parliament and international organizations.
Foundations
Caroline Schmutte, Wellcome Trust
Tobias Kahler, Bill & Melinda Gates Foundation

https://www.globalhealthhub.de/en/content/steering-committee

Global Health Hub Germany



Advisory Board on Global Health (Germany)

Jens Spahn

29. Juli 2019

https://www.globalhealthhub.de/en/news/international-advisory-board-germanys-opportunities-shaping-global-health

29 JUL. 2019 | GLOBAL | BY: JULIA SCHMIDT

Event 201

18. Oktober 2019

https://www.centerforhealthsecurity.org/event201/

Players:
https://www.centerforhealthsecurity.org/event201/players/index.html

Video posted by John Hopkins University:
https://www.youtube.com/watch?v=AoLw-Q8X174&list=PL9-oVXQX88esnrdhaiuRdXGG7XOVYB9Xm

Johns Hopkins Bloomberg School of Public Health
Center for Health Security
World Economic Forum
Bill & Melinda Gates foundation

Event 201 was supported by funding from the Open Philanthropy Project.

https://www.centerforhealthsecurity.org/event201/about



World Health Summit

Berlin, Germany

https://www.worldhealthsummit.org/summit/speakers.html

WORLD HEALTH SUMMIT
OCTOBER 24-26, 2021
BERLIN, GERMANY & DIGITAL
SCIENCE · INNOVATION · POLICIES
SUMMIT 2021 ABOUT PARTNERS INITIATIVES M8 ALLIANCE NEWSROOM COMMUNITY COVID-19 PLATFORM REGIONAL MEETINGS
Home > Partners > Sponsoring Partners
SPONSORING AND SUPPORTING PARTNERS
STRATEGIC PARTNERS
MAJOR PARTNERS
GENERAL PARTNERS
SUPPORTING PARTNERS
NEWSLETTER
Get insights on global health, read about M8 Alliance and community activities, and stay up-to-date with the World Health Summit program: Sign up for our newsletter here
PATRONS 2021
The World Health Summit is traditionally held under the patronage of:
Angela Merkel
Chancellor of the Federal Republic of Germany
Emmanuel Macron
President of the French Republic
Ursula von der Leyen
President of the European Commission
Tedros Adhanom Ghebreyesus
Director-General of the World Health Organization (WHO)
KAMPALA DECLARATION
The World Health Summit Regional Meeting in Uganda ended with the Kampala Declaration on COVID-19 Vaccine Equity, signed by the Director-General of WHO, the President of Uganda, several ministers from Africa, the M8 Alliance, and the World Health Summit.
Find the declaration and all details on the Regional Meeting here
M8 ALLIANCE EXPERT MEETINGS 2021
Next Webinar: November 30, 2021
More information
WORLD HEALTH SUMMIT PRESIDENT
Axel R. Pries, Dean of Charité - Universitätsmedizin Berlin is World Health Summit President since 2021.
Read more

https://www.worldhealthsummit.org/partner/sponsoring-partners.html

Jens Spahn, CDU, Bundesgesundheitsminister



https://www.tagesspiegel.de/politik/privater-immobiliendeal-des-gesundheitsministers-jens-spahn-ist-seiner-verantwortung-nicht-gerecht-geworden/26741038.html
https://www.spiegel.de/politik/deutschland/jens-spahn-villa-in-berlin-dahlem-kostete-4-125-millionen-euro-a-d8a665b4-4746-4ce8-898b-a1eb6713b0dd
https://lobbypedia.de/wiki/Jens_Spahn
https://de.wikipedia.org/wiki/Jens_Spahn https://cdn.businessinsider.de/wp-content/uploads/2021/04/Liste.pdf (Jens Spahn - please see page 4 and 5)



WELT

Ticker Suche Anmelden ABONNEMENT

HOME LIVE-TV MEDIATHEK WELTPLUS BUNDESLIGA POLITIK WIRTSCHAFT SPORT PANORAMA WISS MEHR PRODUKTE

NEWSTICKER DIE NACHRICHTEN HEUTE: Newsticker, Schlagzeilen und alles, was heute wichtig ist, im Überblick. ZUM NEWSTICKER

HOME » PANORAMA » Peter Piot: „Ohne einen Coronavirus-Impfstoff werden wir nie wieder normal leben können"

PANORAMA

CORONAVIRUS-LIVETICKER CORONAVIRUS: ALLE KARTEN UND ZAHLEN

WELT+ PETER PIOT

„Ohne einen Coronavirus-Impfstoff werden wir nie wieder normal leben können"

Veröffentlicht am 13.05.2020 | Lesedauer: 4 Minuten

Von Cornelia Karin Hendrich
Redakteurin

Peter Piot warnt: Das Coronavirus sei eine "lebensverändernde Erfahrung"

Quelle: FABRICE COFFRINI/AFP via Getty Images

Einen Hauch des Todes habe er bei seiner Begegnung mit Covid-19 gespürt, sagt Peter Piot. Der Arzt und Wissenschaftler berät Ursula von der Leyen, zuletzt war er selbst an Corona erkrankt. Ohne Impfstoff werde es kein normales Leben mehr geben.

Der Wissenschaftler und Arzt Peter Piot, Mitentdecker des Ebola-Virus, hat nach seiner eigenen Erkrankung mit Covid-19 vor Langzeitfolgen des neuartigen Coronavirus für viele Menschen gewarnt. Der vielfach ausgezeichnete Forscher, der auch Sonderberater der Präsidentin der EU Kommission, Ursula von der Leyen, ist, sagte: „Es wird weltweit Hunderttausende von Menschen geben, möglicherweise mehr, die für den Rest ihres Lebens Behandlungen wie eine Dialyse benötigen."

https://www.welt.de/vermischtes/plus207946977/Peter-Piot-Ohne-einen-Coronavirus-Impfstoff-werden-wir-nie-wieder-normal-leben-koennen.html



European Commission

Search

Home > Research and Innovation > Events > Upcoming events > European Research and Innovation Days > Speakers > Peter Piot

Peter Piot

Peter Piot is the Director of the London School of Hygiene & Tropical Medicine and Special Advisor to the President of the European Commission on COVID-19. He was the founding Executive Director of UNAIDS and Under Secretary-General of the United Nations from 1995 until 2008. He co-discovered the Ebola virus in 1976 and conducted pioneering research on HIV/AIDS.

Organization

London School of Hygiene & Tropical Medicine

Position

Director

See all speakers

Share this page

Twitter Facebook LinkedIn E-mail More share options

E-mail

European Commission website

This site is managed by the Directorate-General for Research and Innovation

More information on:

Strategy
About the European Commission
Business, Economy, Euro
Aid, Development cooperation, Fundamental rights
Food, Farming, Fisheries
EU regional and urban development

https://ec.europa.eu/research-and-innovation/en/events/upcoming-events/research-innovation-days/speakers/peter-piot
https://www.leopoldina.org/fileadmin/redaktion/Mitglieder/CV_Piot_Peter_EN.pdf



Menu

BILL & MELINDA GATES foundation

Search

Home / Ideas / Media Center / Dr. Peter Piot Joins Foundation as a Senior Fellow

Dr. Peter Piot Joins Foundation as a Senior Fellow - Bill & Melinda Gates Foundation

Media contact

Phone:
206-709-3400

Mail:
media@gatesfoundation.org

Bill & Melinda Gates Foundation
Phone: +1.206.709.3400
Email: media@gatesfoundation.org

Share

SEATTLE -- The Bill & Melinda Gates Foundation announced today that Peter Piot, M.D., Ph.D., has joined the foundation's Global Health Program as a senior fellow until April 30. A distinguished academic and accomplished leader in the global effort to fight HIV/AIDS, Piot served from 1995 to 2008 as the founding executive director of the Joint United Nations Program on HIV/AIDS (UNAIDS).

"Peter is a rigorous scientist and a passionate advocate for global health," said Dr. Tachi Yamada, president of the foundation's Global Health Program. "The foundation and our partners will benefit greatly from his deep experience and his insight into the health challenges facing developing countries."

As a senior fellow, Piot will advise the foundation on its global health strategy, including its support for efforts to fight HIV/AIDS and other infectious diseases.

"I am encouraged by the growing enthusiasm and support for improving health in the developing world," said Dr. Piot. "The Gates Foundation has played a central role in making this progress possible, and I look forward to working closely with my colleagues at the foundation to build on this momentum."

While at UNAIDS, Piot built a broad international coalition against the global HIV/AIDS epidemic, including both governments and civil society groups. He successfully advocated for increased funding for and attention to the epidemic. Global investments to fight HIV/AIDS grew from $250 million in 1996 to $10 billion in 2007.

Piot holds a medical degree from the University of Ghent in Belgium. In 1976, while in Zaire pursuing his Ph.D. in microbiology, he co-discovered the Ebola virus. Piot has held several academic positions and pioneered a series of collaborative programs in sub-Saharan Africa, including Project SIDA in Kinshasa, Zaire, the first international program on HIV in Africa.

https://www.gatesfoundation.org/ideas/media-center/press-releases/2009/01/dr-peter-piot-joins-foundation-as-a-senior-fellow

Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA



Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA, Lothar Wieler, Christian Drosten



Hans-Ulrich Holtherm - Neu im Bundesgesundheitsministerium – 03/2020

aerzteblatt.de

Für Autoren ePaper

/ Ärzteblatt / cme / Ärztestellen / Studieren / English Edition

Home Archiv News Themen DÄ plus Politik Medizin

Archiv > Deutsches Ärzteblatt > 11/2020 > Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

PERSONALIEN

Hans-Ulrich Holtherm: Neu im Bundesgesundheitsministerium

Dtsch Arztebl 2020; 117(11): A-557 / B-481

Beerheide, Rebecca

Artikel | Briefe & Kommentare | Statistik

Hans-Ulrich Holtherm, Foto: Bundeswehr

Seit dem 1. März leitet Generalarzt Dr. med. Hans-Ulrich Holtherm (55) die im Bundesgesundheitsministerium (BMG) neu geschaffene Abteilung 6 „Gesundheitsschutz, Gesundheitssicherheit, Nachhaltigkeit". In der Abteilung gibt es zwei Unterabteilungen mit jeweils fünf Fachreferaten, dazu zählen Referate zum nationalen und internationalen Krisenmanagement.

„Dr. Hans-Ulrich Holtherm verbindet durch seine langjährigen Erfahrungen die Themen Gesundheit und Sicherheit im gesamtgesellschaftlichen Ansatz und ist daher Sinnbild für die neue Abteilung 6", heißt es zur Personalie aus dem Ministerium. Der Kommandeur und Ärztliche Direktor des Bundeswehrkrankenhauses Ulm, bei dem er seinen Dienst erst im Januar 2020 antrat, sei Experte in Fragen des öffentlichen Gesundheitsdienstes im Inland sowie durch Erfahrungen mit der Bundeswehr im Ausland auch „sachkundig in der Krisenreaktion und -prävention", so das BMG. Die Gründung dieser neuen Abteilung wurde schon 2019 beschlossen.

Anzeige

Holtherm war bei Auslandseinsätzen im Irak, Afghanistan, im Kongo, in Dschibuti und im Kosovo. Der Generalarzt war bereits 2009 im Zuge der H1N1-Pandemie von der Bundeswehr abgeordnet in das BMG und gehörte auch 2014 dem ressortübergreifenden Ebola-Krisenstab an. 1964 in Rheine geboren, trat er 1983 in die Bundeswehr ein und studierte als Sanitätsoffiziersanwärter in Münster Humanmedizin. Er ist Allgemeinmediziner, Facharzt für Öffentliches Gesundheitswesen mit Zusatzqualifikationen in Tropen-, Flug- und Betriebsmedizin. *Rebecca Beerheide*

https://www.aerzteblatt.de/archiv/213019/Hans-Ulrich-Holtherm-Neu-im-Bun%C2%ADdes%C2%ADge%C2%ADsund%C2%ADheits%C2%ADmi%C2%ADnis%C2%ADter%C2%ADium

https://de.wikipedia.org/wiki/Hans-Ulrich_Holtherm

Paul Zubeill - Neu im Bundesgesundheitsministerium – 02/2021

Paul Zubeil

Ehemann von Hendrik Streeck tritt Stelle im Gesundheitsministerium an

8. Februar 2021 um 16:07 Uhr | Lesedauer: 5 Minuten

Das Bundesgesundheitsministerium hat seinen Sitz in Bonn. Foto: Benjamin Westhoff

Bonn. Der Ehemann des Bonner Virologen Hendrik Streeck, Paul Zubeil, hat am Montag eine Stelle im Bundesgesundheitsministerium am Dienstort Bonn angetreten. Er ist dort Unterabteilungsleiter für europäische und internationale Angelegenheiten.

https://ga.de/bonn/stadt-bonn/partner-von-hendrik-streeck-paul-zubeil-arbeitet-fuer-das-bundesgesundheitsministerium_aid-56131801

Auszug BioNTech – Geschäftsbericht 2019

Unsere Kollaborationen in den Bereichen Infektionskrankheiten und seltene Erkrankungen

Genevant

- Seit 2018 Co-Entwicklungs- und -Kommerzialisierungspartner für fünf mRNA-Proteinersatztherapien bei seltenen Erkrankungen; 50:50 globale Kosten- und Gewinnaufteilung
- Fünf exklusive Onkologie-LNP-Lizenzen für BioNTech. Genevant ist berechtigt, bedeutende kommerzielle Meilensteine für die Onkologie-Lizenzen zu erhalten

Pfizer

- Seit 2018 bestehende Lizenzierungsvereinbarung zur gemeinsamen Entwicklung eines prophylaktischen Grippeimpfstoffs auf mRNA-Basis (BNT161)
- Vorabzahlung, Kapitalinvestition und erste Meilensteinzahlungen in Höhe von 120 Mio. $
- Bis zu 325 Mio. $ an möglichen weiteren Meilensteinzahlungen
- Lizenzgebühren auf weltweiten Absatz auf weltweiten Nettoumsatz im Falle einer Marktzulassung

University of Pennsylvania (UPenn)

- Seit 2018 strategische Forschungs- und Entwicklungskooperation mit der exklusiven Option, mRNA-Immuntherapien zur Behandlung von bis zu zehn Indikationen von Infektionskrankheiten zu entwickeln und zu vermarkten
- Unterstützung der Forschungsaktivitäten seitens BioNTech mit 20 Mio. $
- UPenn führt die präklinischen Studien durch
- BioNTech behält die Option, die mRNA-Impfstoffkandidaten für die klinische Entwicklung zu lizensieren

Bill & Melinda Gates Foundation

- Seit 2019 Forschungs- und Entwicklungsvereinbarung im Bereich HIV und Tuberkulose (TB) sowie bis zu drei weiteren Infektionskrankheiten
- 55 Mio. $ als Equity-Investition in die Entwicklung weiterer Strategien zur Prävention und/oder Behandlung von HIV und TB
- Zuschüsse in Höhe von bis zu 45 Mio. $ zur Finanzierung zusätzlicher Aktivitäten in bis zu drei weiteren Projekten im Bereich Infektionskrankheiten innerhalb der ersten fünf Jahre der Zusammenarbeit

53

Epitop, welches in Bauchspeicheldrüsenkrebs und anderen gastrointestinalen Krebsarten exprimiert wird und dort eine Rolle bei der Tumoradhäsion und Metastasenbildung spielt.

Im Juni 2019 gab BioNTech den Start der klinischen Entwicklung von Produktkandidat DuoBody®-PD-L1x4-1BB bekannt. PD-L1x4-1BB ist ein bi-spezifischer Antikörper, der gemeinsam mit Genmab A/S entwickelt wird. Im Rahmen der Phase-1/2a-Studie wird der bi-spezifische Antikörper in Patienten mit metastasierenden oder chirurgisch nicht entfernbaren soliden Tumoren getestet, die nicht mit der Standardtherapie behandelt werden können. Der DuoBody®-PD-L1x4-1BB ist der erste gemeinsam entwickelte Produktkandidat, der die klinische Phase erreicht. Die Kosten und Gewinne, die im Zuge der Partnerschaft anfallen, werden im Verhältnis 50 zu 50 geteilt. Ziel der 2015 unterzeichneten und 2016 um weitere Zielstrukturen und Technologien erweiterten Zusammenarbeit ist die Entwicklung und Vermarktung mehrerer neuartiger bi-spezifischer Antikörper mit überlegener in-vivo-Wirksamkeit, die das Immunsystem spezifisch gegen Krebszellen aktivieren.

Im September 2019 hat BioNTech eine Partnerschaft mit der Bill & Melinda Gates Stiftung für die Entwicklung von HIV- und Tuberkulose Impfstoffen bekanntgegeben. Im Rahmen dieser Vereinbarung hat BioNTech im September 2019 eine erste Kapitalinvestition in Höhe von 49.864 T€ (55.000 T$) erhalten. Die Finanzierung dient der Entwicklung von präklinischen Impfstoffen sowie Immuntherapiekandidaten für HIV- und Tuberkulose Infektionen, die präventiv eingesetzt werden und im Fall von HIV eine dauerhafte Remission ohne antiretrovirale Therapie ermöglichen sollen. Durch zusätzliche zukünftige Finanzierungsvereinbarungen könnten sich die Gesamtinvestitionen der Gates Stiftung auf bis zu 100.000 T$. belaufen. In diesem Fall wird dieses Kapital für die klinische Entwicklung von Produktkandidaten sowie der Initiierung neuer Projekte in diesem Indikationsbereich verwendet werden.

Finanzierung

KAPITALERHÖHUNG SERIES B

Im Juni und August 2019 hat BioNTech die Series-B-Finanzierungsrunde abgeschlossen, um seine individualisierte Krebsmedizinpipeline weiterzuentwickeln. Hierbei handelt es sich um eine der größten Einzelfinanzierungen eines privaten europäischen Biotechnologieunternehmens. In diesem Zusammenhang gab BioNTech insgesamt 12.465.288 Stammaktien (mit Ausnahme von 5.524.506 Stammaktien, die an einen in Hongkong ansässigen Investor ausgegeben und anschließend aufgrund keiner Gegenleistung wieder an BioNTech übertragen wurden; diese Aktien werden als eigene Anteile gehalten) an neue sowie bestehende Aktionäre zu einem Preis von 18,10 $ pro Aktie für einen Gesamterlös von 198.548 T€ (225.622 T$) aus. Die Kapitalerhöhung erhöhte das gezeichnete Kapital um 17.990 T€ und die Kapitalrücklage um 186.390 T€ sowie die Erfassung von eigenen Anteilen in Höhe von 5.525 T€.

BÖRSENGANG („INITIAL PUBLIC OFFERING – IPO")

Am 10. Oktober 2019 erhöhte BioNTech in Verbindung mit dem Börsengang das gezeichnete Kapital um 10.000 T€. American Depositary Shares (ADS), die Stammaktien repräsentieren, wurden an der Nasdaq Global Select Market zu einem Preis von 15,00 $ angeboten. Am 6. November 2019 erhöhte BioNTech das gezeichnete Kapital um weitere 517 T€ durch die Ausübung der im Zusammenhang mit dem

68

Die nachstehende Tabelle gibt eine Übersicht zu den Aktienoptionen, die in den Geschäftsjahren 2019 und 2018 an Vorstandsmitglieder ausgegeben wurden.

	Zeitpunkt der Ausgabe[1]	Anzahl der den Aktienoptionen zugrunde liegenden Stammaktien[4]	Ausübungspreis (€)	Ablauf der Möglichkeit zur Optionsausübung
Prof. Dr. Ugur Sahin	15.11.2018	1.830.348	10,14	17.9.2026
	10.10.2019[2]	4.374.963	13,60	11.10.2029
Sean Marett	15.11.2018	610.110	10,14	17.9.2026
Dr. Sierk Poetting	15.11.2018	610.110	10,14	17.9.2026
Dr. med. Özlem Türeci	15.11.2018[3]	1.952.334	10,14	17.9.2026

[1] Wenn nicht anders angegeben, werden alle Optionen am 16. September 2022 unverfallbar.
[2] Die Option wird jährlich in gleichen Raten nach vier Jahren, jeweils am 10. Oktober in den Jahren 2020, 2021, 2022 und 2023, unverfallbar.
[3] Die Optionen wurden am 16 März 2019 unverfallbar, gleichwohl kann die Ausübung erst ab dem 16. September 2022 erfolgen.
[4] Die Anzahl der Stammaktien bildet den Effekt der Kapitalerhöhung aufgrund eines Aktiensplits von 1:18 ab, der Am 8. September 2019 mit der Eintragung im Handelsregister wirksam wurde.

92

https://investors.biontech.de/static-files/5e4133c2-6e8f-4ca4-8a65-ffa97007d9eb

Link Analysis

Simple extract of links between Gates Foundation and other NGOs /GOVs



WHO – World Health Organization



PATH


BMGF - Bill & Melinda Gates Fou...
Financed
Finance in 2016
Finance > 2,4Mrd letzten 10 Jahre
Finance / Partner indirect Finance via World Bank
Executive Member
Grants
Finance
work for (President)
Founded by
Health Strategies at the Bill & Melinda Gates Foundation
MSD / Merck
The Rockefeller Foundation
Johnson & Johnsen
Christopher Elias
Pfizer
Funding
Fincance ? Amount
Finacne ? Amount
https://r4d.org/about/partners-and-funders/
Member of/Seat
SIXTH INVESTORS GROUP MEETING
Former President/ CEO
GAVI
The Global Good Fund
Finance
Finance ? Amount
Steve Davis
David Fleming, MD
Vasee Moorthy
Nikolaj Gilbert
Novartis Foundation
GFF - Global Financing Facility...
Executive Roundtable
Vice President, Global Health Programs
President and CEO
Partner
PATH
Difficulties in India
Executive Member
Financed
King County - Public Health - S...
MVI Malaria Vaccine Inititaive ...
Addintional Information
WGHA - Washington Global Health...
R4D - Results for Development


CARB-X
BMGF - Bill & Melinda Gates Fou...
ASPR - Assistant Secretary for ...
BMBF - Bundesministerium für Bi...
UKAID
Finance
Finance $726,249,461
Finance Foundation Partner
Finance
Division
Funder
Donor
Finance 40 Mio - 5 Years
Donor
Funder
MMV - Medicines for Malaria Ven...
C-CAMP - Centre for Cellular an...
Cystic Fibrosis Foundation
DZIF - Deutschen Zentrum für Inf...
RTI International
NIH - National Institutes of He...
BARDA - Biomedical Advanced Res...
Wellcome Trust
ILSE - Institute for Life Scien...
FIND
MassBio - Massachusetts Biotech...
DTRA - The Defense Threat Reduc...
California Life Sciences Instit...
Screening Partners
CARB-X Global Accelerators
Screening Partners
CARB-X Global Accelerators
CARB-X Global Accelerators
Funders
Funder 180 Mio
CARB-X Global Accelerators
CARB-X Global Accelerators
CARB-X Global Accelerators
Screening Partners
CARB-X Global Accelerators
CARB-X
Financed 1,4 Mio
Zusätzlich zur direkten Förderung von CARB-X fördert das BMBF im nationalen Maßstab mit rund 1 Mio. Euro den sogenannten „CARB-X-Accelerator
HZI - Helmholtz-Zentrum für Infe...
PEI Paul-Ehrlich-Institut


GIZ
Bill & Melinda Gates Foundation
Mitglied
Financed $6.150.971
SEEK Development, Strategic and...
Client
Client
Client
BMZ - Federal Ministry for Econ...
??
GIZ Deutsche Gesellschaft für I...
Agenda 2030
PharmAccess Foundation
Mitglied
Global Health Hub Germany



Almost all of these individuals' employers receive donations from the Gates Foundation.

https://www.wghalliance.org/

WGHA - Washington Global Health Alliance AND Board Members of University of Washington - Department of Health



MMV


BMGF - Bill & Melinda Gates Fou...
Finance $726.249.461
Finance
Financed /Alliance Partner
Former Senior Advisor
David Brandling-Bennett
Mike Ferguson
Government of Switzerland
The World Bank
The Rockefeller Foundation
Netherland
GOV.UK
Trevor Gibbs
Board of Director
member of the Board of Directors
Financed / Founder
Financed / Founder
Financed / Founder
Independent Consultant
MMV - Medicines for Malaria Ven...
Screening Partners
CARB-X
CARB-X

Adjuvant Capital



Merck


BMGF - Bill & Melinda Gates Fou...
Belén Garijo
Kenneth C. Frazier
JULIE LOUISE GERBERDING
Financed $1.390.164
Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines - Finalized $82.681.410
Vice Chair of the Executive Board
Board of Directors
Merck
Commitments to Expanded Global Access for COVID-19 Diagnostics, Therapeutics, and Vaccines
Merck, BMS chip in to PathAI's series B, bringing total to $75M
Life Science Companies and the ...
Evotec / Just-Evotec Biologics,...
GAVI
PathAI
Adjuvant Capital
RED
Hilleman Laboratories
Finance ? Amount
Partners
IVI - International Vaccine Ins...
PATH
Partners
Developing Countries Vaccine Ma...

Merck + Jule Louise Gerberding (direct connections)



Pfizer



https://www.pfizer.com/people/leadership/board-of-directors

Johnson & Johnson



IVI - International Vaccine Institute



ID2020


Seth Berkley
Bill Gates
The Rockefeller Foundation
Funding
Board Member
CEO
Founder / Shareholder
Founding
Founding Partner
GAVI
accenture
Microsoft
Kim Gagné
IDEO ORG
Founding Partner
Founding Partner
Founding Partner
Board Chariman
Founding Partner
ID2020
Partner
National Cybersecurity Center

ONE


BMGF - Bill & Melinda Gates Fou...
is working for (as Managing Director, Global Policy & Advocacy, Bill & Melinda Gates Foundation)
Finance $199.168.587
Joe Cerrell
Bono
friend
friend
Jamie Drummond
Sheryl Sandberg
data.org
Gayle E. Smith
Tobias Kahler
Morton H. Halperin
Co-Founder / Board
Members of the Board of Directors / Co-fo
Member of the Board of Directors
Members of the Board of Directors
ONE
ONE
Sister-Organization / Poliicy Founder
RED

ONE


BMGF - Bill & Melinda Gates Fou...
YGL - Young Global Leaders
Joe Cerrell
Tobias Kahler
Bono
Global Health Hub Germany
APCO Worldwide
CDU / CSU - Globale Gesundheit
Jamie Drummond
Global Citizen
Gayle E. Smith
Save the Children
Rajiv Shah
Sheryl Sandberg
data.org
Morton H. Halperin
Peter A Singer
USAID
2021-01-12/32 Some Future forum...
ONE
Facebook
Open Society Foundations
Seth Berkley
RED


IFPMA - International Federation of Pharmaceutical Manufacturers & Associations
Albert Bourla
Jean-Christophe Tellier
IFPMA President and Chair of the IFPMA CEO Steering Committee, Chief Executive
Committee, UCB
Pfizer
Isao Teshirogi
Novartis
Sanofi
Novo Nordisk
Gilead Sciences, Inc.
Bayer AG
AstraZeneca
Eli Lilly and Company
34
UCB
Full Member
Full Member
Full Member
Full Member
Full Member
Collaboration Partner
Collaboration Partner
Collaboration Partner
Collaboration Partner
IFPMA - International Federatio...
??
Project / Part of IFPMA
GAVI
Global Health Progress


PharmAccess Foundation
Norad
Department for International De...
Deutsche Bank
ADB - Asian Development Bank
Calvert Impact Capital
Grand Challenges Canada
PharmAccess Group
Saving Lives At Birth
IFC Internation Finance Corpora...
Sanofi
JCM - The John C. Martin Founda...
Bill & Melinda Gates Foundation
USAID
UKAID
PharmAccess Foundation
Clinton Foundation
International Labour Organizati...
GIZ Deutsche Gesellschaft für I...
kfw Entwicklungsbank
The Rockefeller Foundation
Global Health Hub Germany
FMO Entrepeneurial Development ...
Netherland Organisation for Sci...
CIFF - Children's Investment Fu...
Boeringer Ingelheim
OPIC
European Vaccine Initiative (EV...
Partner
Public funders and investors
Private investors and funders
Financed
Finance
Private Investors and donors
Public donors and investors
Private investors and donors
Mitglied
Finance 127 Mio!!
Steering Commitee


data.org
Jamie Drummond
Bill & Melinda Gates Foundation
Co-Founder / Board
Members of the Board of Directors / Co-founder ONE
friend
is working for (as Managing Director, Global Policy & Advocacy, Bill & Melinda Gates
friend
Wellcome Trust
Joe Cerrell
The Rockefeller Foundation
Founder
Worked for
Finance
Bono
Danil Mikhailov
Sheryl Sandberg
NewVentureFund
Co-Founder
Associate Director, RoRI
CEO
Members of the Board of Directors
Sponsor
RORI - Research On Research Ins...
360Giving - https://www.threesi...
data.org
Gayle E. Smith
Morton H. Halperin
Tobias Kahler
belongs to
global movement campaigning
ONE
ONE
Sister-Organization / Policy Founder
RED

CGD - Center for Global Development



NTI - Nuclear Threat Initiative (1 Level)



NTI - Nuclear Threat Initiative
+ Direct Linked Persons (1 Level)


Africa Centres for Disease Cont...
Some Future forum on Prepardnes...
RKI Robert Koch Institut - Scie...
CDC - Centers for Disease Contr...
John Nkengasong
Director
Speaker
Board Member
Wellcome Trust
Founder
CEPI Coalition for Epidemic Pre...
Host
Bio Advisory Group
He serves on several international advisory boards including IAVI
He serves on several international advisory boards including the Coalition for Epidemic Preparedness Initiative - CEPI
Member - Vaccines and Drug-resistant Infections Strategic Advisory Board
IAVI
Working Group members
Biosecurity Innovation and Ris...
Attendee
Board of Directors
Finance
Grants
ESTABLISHING A SEAL OF APPROVAL...
NTI - 2018-10-29 - Biosecurity ...
Author
Jaime Yassif
Senior Fellow, Global Biological Policy and Programs
Open Philanthropy
NTI - Nuclear Threat Initiative
Host
he is the immediate past Chair/President
BMGF - Bill & Melinda Gates Fou...
Funded
Grants
Founded by
Member
AAAS - American Association for...
She served as an American Association for the Advancement of Science (AAAS) Fellow at the State Department and in the health policy office of Senator Edward M. Kennedy where she worked on the Patients' Bill of Rights, medical privacy, and legislation to improve the quality of cancer care
National Academies of Sciences,...
GAVI
The Urban Institute
CSIS - Center for Strategic and...
Organizer
Sponsor
Attendee
Beth Cameron was formerly NTI's vice president for global biological policy and programs.
NTI - 2019-05-29 - bio Focuses ...
NTI - 2019-12-xx - Washington,...
Published by WEF / NTI
Speaker
Beth Cameron
Advisor
Trustee
Warren E. Buffett
Founder
The Giving Pledge
Chairman of the Board and Chief Executive Officer
Berkshire Hathaway
Contributors
Project Team
NTI - 2019-02-14 - Tabletop Exe...
Atlantic Storm (2005)
Biosecurity Innovation and Risk...
Wilton Park - 2018-11-07/8/9
Margaret A. Hamburg
EXTERNAL ADVISORY BOARD
Board
Former
Board of Directors
Council on Foreign Relations
NIAID - National Institute of A...
The Commonwealth Fund
The Simons Foundation
Alnylam Pharmaceuticals
University of Washington - Depa...
The Nature Conservancy
Clade-X
GLOBAL BOARD
Player
Former FDA Commissioner
FDA
Non-voting members
Working Group members
Key Player
Member of BMGF Scientific Advisory Committee
BMGF Scientific Advisory Commit...
Dark Winter (2001)
Board Member
The Dark Winter exercise was the collaborative effort of 4 organizations. John Hamre of the Center for Strategic and International Studies (CSIS) initiated and conce

NTI - Nuclear Threat Initiative (Addintional Information)

https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/

https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/biosecurity-innovation-and-risk-reduction-initiative-launch/

https://media.nti.org/documents/Biosecurity_Innovation_and_Risk_Reduction.pdf

https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf

https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf

https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf

CSIS - Center for Strategic and International Studies / Strengthening America's Health Security



CSIS - Center for Strategic and International Studies / Strengthening America's Health Security





https://www.who.int/bulletin/online_first/BLT.17.205005.pdf



https://www.who.int/bulletin/online_first/BLT.17.205005.pdf

METABIOTA (Level 2 Connections


Wellcome Trust
Provides funding for the Wellcome Trust-funded VIZIONS program
Provides funding for the VIZIONS program through University of Oxford. http://www.oucru.org
Care International
University of Oxford
USAID
US Department of Defense
Caltech - California Institute ...
ASM - The American Society for ...
THE RICHARD LOUNSBERY FOUNDATION
JGI - Joint Genome Institute
Stanford University
John Templeton Foundation
Global Viral
Financial Advisor
The Pew Charitable Trusts
PRC is a subsidiary
Pew Research Center
Content Partner of WEF
WEF - World Economic Forum
Author
YGL - Young Global Leaders
EDWARD RUBIN
DARPA
Board Member, Author
Member of Young Global Leaders is member of DARPA's
Founder 2007
GVP - Global Virome Project
Nathan D. Wolfe
GenomeCanada
Founder & Chairmann
Provides funding for the Department of Defense HIV/AIDS Prevention Program and USAID Predict 2 program
Document - The Global Virome Pr...
METABIOTA



http://www.healthdata.org/about/governance/board

IHME - The Institute for Health Metrics and Evaluation incl. direct connections of Members





Pentagon tasks Pfizer with radically rethinking vaccine development - https://www.fiercepharma.com/r-d/pentagon-tasks-pfizer-radically-rethinking-vaccine-development (2013-12-09)
BARDA - Rapidly advancing a Zika mRNA vaccine / DARPA – Advancing mRNA therapies and vaccines for biodefense
- https://www.modernatx.com/ecosystem/strategic-collaborators/mrna-strategic-collaborators-government-organizations (09/2016 & 10/2013)

Selected Views

Peter Piot
Lothar Wieler
Victor Dzau
Georg F Gao
Jeremy Ferrar
Christian Drosten
Ralph S. Baric
Peter Daszak



CDC - 1 Level


David Fleming, MD
John Nkengasong
Tom Frieden
Deborah Birx
JULIE LOUISE GERBERDING
Jacquelline Quay
Former Deputy Director
CDC - Centers for Disease Contr...
Funding Partners
Donor
IANPHI - The International Ass...
CDC Foundation
FIND
Patent - US7220852B1 - Coronavi...

CDC - Director / Former Director - 1 Level


JULIE LOUISE GERBERDING
Player
Clade-X
Board of Directors
CO-CHAIRS
Served as Director of the U.S. Centers for Disease Control and Prevention (CDC) from 2002 to 2009.
Executive Vice President and Chief Patient Officer at Merck
Cerner Corporation
Cerner provides Data to BMGF
John Nkengasong
BMGF - Bill & Melinda Gates Fou...
Tom Frieden
Jacquelline Quay
Funded
Grants
Financed (indirect)
Finance
Financed
Financed $1.390.164
Finance > 2,4Mrd letzten 10 Jahre
Chief Executive Officer at Resolve to Save Lives
Member
Author
Former Director 2009-2017
Director Licensing & Innovation Support OTC
Board Member
Director
Speaker
He serves on several international advisory boards including IAVI
He serves on several international advisory boards including the Coalition for Epidemic Preparedness Initiative - CEPI
He has previously held positions as the director of Global Health Strategies at the Bill & Melinda Gates Foundation
RKI Robert Koch Institut - Some...
Future forum on Preparednes...
CEPI Coalition for Epidemic Pre...
IAVI
Executive Member
David Fleming, MD
MSD / Merck
GPEI - Global Polio Eradication...
Resolve to Save Lives
Deborah Birx
CSIS - Center for Strategic and...
The University of North Carolin...
Global health security: the wid...
Africa Centres for Disease Cont...
Fincance ? Amount
EXTERNAL ADVISORY BOARD
Vice President, Global Health Programs
Former Deputy Director
Executive Roundtable
Former director of Centers for Disease Control and Prevention's Division of Global HIV/AIDS (DGHA), part of the agency's Center for Global Health (2005 - 2014)
Jjoint-venture Merkc & Wellcome Trust
University of Washington - Depa...
PATH
CDC - Centers for Disease Cont...
Fauci Leaked E-Mails
Dark Winter (2001)
Hilleman Laboratories
Leaked NDA Moderna / NIAD
Executive Member
Executive Member
WGHA - Washington Global Health...

Contributors of selected documents



1 - Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19 https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2930418-9
2 - Leopoldina-Stellungnahmen zur Coronavirus-Pandemie (2020) https://www.leopoldina.org/publikationen/detailansicht/publication/leopoldina-stellungnahmen-zur-coronavirus-pandemie-2020/
3 - Laboratory testing of 2019 novel coronavirus (2019-nCoV) in suspected human cases: interim guidance, 17 January 2020 https://apps.who.int/iris/rest/bitstreams/1266309/retrieve
4 - Document - The Global Virome Project https://www.who.int/bulletin/online_first/BLT.17.205005.pdf
5 - Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR (2020-01-13) https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2

The Global Virome Project



https://www.globalviromeproject.org/
https://www.who.int/bulletin/online_first/BLT.17.205005.pdf

The Global Virome Project



Peter Piot & Heidi Larson - additional links




Ralph S. Baric - 1 Level
Ralph S. Baric
Author
Author
Inventor
Inventor
Author
Inventor
Member
Inventor
Former Postdoctoral Fellows - see CV Ralph Baric
Speaker
Inventor
iddle East Respiratory Syndrom...
CV Ralph Baric
National Academies of Sciences,...
Possibility for reverse zoonoti...
Patent US 6593111B2 - DIRECTION...
Patent # 7618802 - Compositions...
READDI - Rapidly Emerging Antiv...
Rachel Graham
YouTube: Imagining the Next Flu...
Patent US7279327 B2 - METHODS F...
Kizzmekia S. Corbett
Patent# US9884895B2 - METHODS A...
U19 AI107810 - Characterization...
Patent USUS20110070260A1 - MULT...
Author
ASSISTANT PROFESSOR DEPARTMENT OF EPIDEMIOLOGY
U19 AI100625 Systems Immunogene...
The University of North Carolin...
Publications
Leaked NDA Moderna / NIAD


Ralph S. Baric - 2 Level
NIH - National Institutes of He...
Barney Graham
Boyd Yount
Ralph S. Baric
Kristopher M. Curtis
Mark Heise
Christian Drosten
Nathaniel Moorman
BMGF - Bill & Melinda Gates Fou
Tara O'Toole
JONNA MAZET
PETER DASZAK
Harvey Fineb
Jonathan Epstein
Margaret A. Hamburg
NIAD National Institute of Alle...
Rachel Graham
Patent US 6993182 - DIR
Patent US 9884589 B2 - METHOD
Ralph Baric
Patent US US20110070260A1 - TIT
Imagining the Next Flu...
Patent US7279327 B2 - MET
7618802 - Compositions...
Middle East Respiratory Syndrom...
READDI - Rapidly Emerging Anti...
Possibility for reverse zoonotic
National Academies of Sciences,...
Jacqueline Quay
moderna
Amy Petrik
U19 AI107810 - Characterization...
U19 AI100625 Systems Immunogene...
Kizzmekia S. Corbett
Publications
The University of North Carolin...
Shaun Ryan
Sunny Himansu
NIADs VRC - Vaccine Research Ce...
Leaked NDA Moderna / NIAD
Some Future forum on Preparedne...

Selected Persons - Event Atlantic Storm / Clade-X / Event 201 / Dark Winter




YGL - Young Global Leaders - 1 Level
Klaus Schwab
Founder / CEO
Founder
WEF - World Economic Forum
Author
Author for WEF
Author / Contributor
3.3K
YGL - Young Global Leaders
Attendee 2008
Esther Duflo
Akihiko Tanaka
Yoshikazu Tanaka
David Jones
Thomas J. Bollyky
Sheryl Sandberg
Rajiv Shah
Jens Spahn
Nathan D. Wolfe
Kate Robertson
Fareed Zakaria
Angela Merkel
Mark Zuckerberg
Sergey Brin
Nilmini Rubin
Eric Schmidt
Bono

Selected Persons - YGL



YGL Members and their direct connection to existing objects.



Tara O'Toole and In-Q-Tel



IT

Google


Kate Brandt
Larry Page
Eric Schmidt
Regina Dugan
Ken Gabriel
Sergey Brin
Melike Yetken
Co-Founder
Head
Google
Google
Partner of WEF
FULL FACT
FullFact
Google News Initiative
Google New Initiative
WORLD ECONOMIC FORUM
WEF - World Economic Forum
msc
Munich Security Conference
FACTCHECK.ORG
Munich Security Conference / FactCheck.org


Facebook
Mark Zuckerberg
Nilmini Rubin
Regina Dugan
Sheryl Sandberg
Founder and Chief Executive Offi
International Public Policy Manager
Facebook (2017-2018)
GF
Facebook
Grants
Grants, Sponsor
of WEF
Poynter Institute
msc
Munich Security Conference / Si...
Facebook Journalism Project
FULL
FACT
FullFact
FactCheck.org
WORLD
ECONOMIC
FORUM
WEF - World Economic Forum

“EXERCISES”


Dark Winter (2001)
Mary Walsh
John Hopkings Bloomberg Public ...
Sian Edwards
Host
Key Player
Frank Wisner
Jim Miklaszewski
Jerome Hauer
Lester Reingold
John Tilelli
George Terwilliger
Judith Miller
Sam Nunn
John White
Dan Mahoney
Tara O'Toole
Dark Winter (2001)
Randy Larsen and Mark DeMier of Analytic Services, Inc., (ANSER) were the principal designers, authors, and controllers of Dark Winte
General Dennis Reimer of the Memorial Institute for the Prevention of Terrorism (MIPT) provided funding for Dark Winter.
MIPT -Memorial Institute for th...
David Gergen
Frank Keating
Tara O'Toole and Tom Inglesby of the Johns Hopkins Center for Civilian Biodefense Studies
Sue Reingold of CSIS managed administrative and logistical arrangement
Tom Frieden
Randy Larsen
R. James Woolsey
Member
The Dark Winter exercise was the collaborative effort of 4 organizations. John Hamre of the Center for Strategic and Internatio
Sue Reingold
work for
Randy Larsen and Mark DeMier of Analytic Services, Inc., (ANSER) were the principal designers, authors, and controllers of Dark Winte
CSIS - Center for Strategic and...
Margaret A. Hamburg
William Sessions
work for
John Hamre of the Center for Strategic and International Studies (CSIS) initiated and conceived of an exercise wherein senior former officials w
Mark DeMier
John Hamre

https://www.centerforhealthsecurity.org/our-work/events-archive/2001_dark-winter/about.html



https://www.centerforhealthsecurity.org/our-work/events-archive/2005_atlantic_storm/index.html

Clade-X (2018)



https://www.centerforhealthsecurity.org/our-work/events/2018_clade_x_exercise/
https://www.weforum.org/agenda/2018/07/infectious-disease-pandemic-clade-x-johns-hopkins/

Event 201 (2019-10-18)



NTI - 2018-07-20/21 - Constructive discussion during the June 20-21, 2018 Meeting on biological risk hosted by the Wellcome Trust, NTI, and the World Economic Forum in London



List of participants not available...

https://www.nti.org/newsroom/news/nti-bio-partners-wellcome-trust-and-world-economic-forum-host-meeting-biosecurity-innovation-and-risk-reduction/

NTI - 2018-10-29 - Biosecurity Innovation and Risk Reduction Initiative Launch



https://www.nti.org/about/projects/fostering-biosecurity-innovation-and-risk-reduction/
https://media.nti.org/documents/Biosecurity_Innovation_and_Risk_Reduction.pdf
https://media.nti.org/documents/Initiative_Participants_and_Initiative_Members_List_October_29_Kickoff.pdf
https://media.nti.org/documents/NTI_Paper_5_Establishing_a_Seal_of_Approval_to_Incentivize_Adherence_to_Biosec_a5iL1rO.pdf

https://media.nti.org/documents/NTI_Initiative_-_Paper_2_-_Instituting_Biosecurity_Investment.pdf
https://media.nti.org/documents/NTI_Initiative_-_Paper_6_-_Additional_Topics_for_Potential_Discussion.pdf
https://media.nti.org/documents/NTI_Initiative_-_3_-_Standards_for_Funders_and_Grantees_to_Identify.pdf
https://media.nti.org/documents/NTI_Initiative_-_Paper_4_-_Insurance_Incentives_for_Reducing_Biological_Risks.pdf
https://media.nti.org/documents/NTI_Initiative_-_Paper_1_-_Universal_Platform_to_Prevent_Illicit_Gene_Synthesi_zVnWfjM.pdf

NTI - 2019-02-14 - Tabletop Exercise on International Response to Deliberate Biological Events Munich Security Conference



https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf
https://media.nti.org/documents/NTI_Paper_A_Spreading_Plague_FINAL_061119.pdf
https://media.nti.org/documents/Participants_List_TTX_on_Deliberate_Bio_Event_2019_MSC_2.14_FINAL.pdf

NTI - 2019-05-29 - bio Focuses on High-Consequence, Deliberate, and Global Catastrophic Biological Risks During World Health Assembly Side Event



https://www.nti.org/newsroom/news/nti-bio-focuses-high-consequence-deliberate-and-global-catastrophic-biological-risks-during-world-health-assembly-side-event/

NTI - 2019-12-xx - Washington, DC Tabletop Exercise Participants



https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf

NTI - 2020-02-xx - 2020 Munich Security Conference Tabletop Exercise Participants



https://media.nti.org/documents/NTI_BIO_TTX_RPT_FINAL.pdf

Wilton Park - 2018-11-07/8/9 - Powerful actor, high impact bio-threats

Munich Security Conference / Sicherheitskonferenz München



Members of several Advisory Boards and related exercises/events



“Meetings”

Public Congress on Global Health for
CDU/CSU Parliamentary Group
2019-05-08



2021-01-12/32 Some Future forum on Prepardnes (SCHMIDT FUTURES)



“Gang”

BMGF Scientific Advisory Committee


BMGF - Bill & Melinda Gates Fou...
Shabir A. Madhi
Margaret A. Hamburg
John Bell
Yvonne Greenstreet
Eric G. Pamer
Tumani Corrah
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Chair of Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
BMGF Scientific Advisory Commit...
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Member of BMGF Scientific Advisory Committee
Zulfiqar A. Bhutta
Francine Ntoumi
Timothy M. Wright
Gagandeep "Cherry" Kang
Harold Varmus
H. Robert Horvitz
Alan Bernstein
Salim S. Abdool Karim

Commission's advisory panel on COVID-19 (E03719)



Eurosurveillance editorial board (2 Level)



International Advisory Board on Global Health



NTI - Expert Contributors to Scenario Development



RKI Robert Koch Institut - Scientific Advisory Board for the Centre for International Health Protection (ZIG)



Connections between Georg F. Gao (Chinese CDC), Chris Elias (Gates Foundation), Christian Drosten (Charite), Lothar Wieler (Robert Koch Institut), Jeremy Farrar (Wellcome Trust)



Connections between Lothar Wieler (Robert Koch Institut), Jeremy Farrar (Wellcome Trust), Joachim Sauer (Leoplodina), Georg F. Gao (Chinese CDC), Peter Piot (Commissions Adivsory Panel, Gates Foundation Senior Fellow),, Christian Drosten (Charite), Chris Elias (Gates Foundation), Ilona Kickbusch, Hans-Ulrich Holtherm (BGM)



Commission's advisory panel on COVID-19 (E03719)
https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?lang=en&groupId=3719&fromMeetings=true&meetingId=20410

International Advisory Board on Global Health
https://www.bundesgesundheitsministerium.de/english-version/press/international-advisory-board.html

CDU / CSU - Globale Gesundheit stärken UN-Nachhaltigkeitsziel umsetzen (https://www.cducsu.de/veranstaltungen/globale-gesundheit-st-rken-un-nachhaltigkeitsziel-umsetzen/referenten)

NTI - 2019-02-14 - Tabletop Exercise on International Response to Deliberate Biological Events Munich Security Conference

Sample of Public Private Partnership

Open Letter to Biden Administration – 3rd August 2021

"US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security"

https://healthpolicy.duke.edu/sites/default/files/2021-08/USEPCR%20Cover%20letter_FINAL_For%20Distribution.pdf

US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security

We are at an exceedingly perilous and urgent moment in the COVID-19 pandemic. The Delta variant, vastly more dangerous and pernicious than the original SARS-CoV-2 virus, has rapidly spread worldwide. It has been driving a deadly summer surge in the US; ripping through Latin America; causing Indonesia to become the next Asian hotspot; and fueling a third wave of the pandemic in Africa, where less than two percent of the population has been fully vaccinated.

To respond, the US must build on the rapid development and availability of its highly effective vaccines – ensuring easy access for any American who wants to be vaccinated, and readiness to rapidly deploy boosters and vaccines for children. But as Delta has shown, an effective domestic response is not enough.

We are in a global war against a virus that doesn't respect borders and rapidly advances across continents. If the virus continues to circulate largely unchecked in many parts of the world, there is a very real prospect of new variants emerging that could totally pierce vaccine immunity, returning America and the rest of the world to square one.

The only way to prevent such a catastrophe is to dramatically decrease cases and slow transmission of the virus through widespread global vaccination, combined with other public health measures. Inequitable access to high-quality vaccines threatens to prolong the pandemic and destabilize economies and societies around the world.

To date, 82 percent of all COVID-19 vaccine doses that have gone into arms worldwide have been administered in high- and upper middle-income countries. By contrast, less than one percent have been administered in low-income countries. Meanwhile, COVAX, the multinational vaccine facility, is struggling to meet this challenge, having distributed only 153 million doses out of 4.1 billion administered worldwide.

We are facing the very real possibility that low- and lower-middle income countries will be stuck at low vaccine coverage levels through 2022 and beyond, an outcome that will be deadly. The deep divide between vaccine haves and have-nots is a challenge to our conscience and a major threat to our economic recovery and national security.

Fortunately, the supply of high-quality vaccines produced by US and allied manufacturers is projected to exceed 7 billion doses in 2021 and 14 billion doses in 2022 – more than enough to protect Americans and vaccinate the world. But doing so will require coordinated action by the US, other nations, and manufacturers to finance, allocate, and deliver doses where they are most acutely needed.

The US is on track to have over 1 billion excess doses, even assuming vaccinations and boosters for the entire population. This means we can combat the Delta-driven surge at home, while at the same time donating doses to combat it abroad. Indeed, we can – and must – do both simultaneously. This world war requires a global plan of attack.

The US and G7 allies have taken important but modest steps to close the global vaccine gap, including by accelerating large-scale production and delivery of high-quality vaccines, increasing financial support to COVAX, and committing to share roughly 900 million doses over the next year (including 580 million from the US). But these actions fall far short of the true scale and urgency required.

Much more needs to be done to provide high-quality vaccines more quickly, and to build countries' vaccine distribution and delivery capacity, which is rapidly becoming the key constraint in the race between vaccines and variants.

With the global situation becoming more dire, and current global efforts proving to be woefully insufficient, urgent US leadership is needed to get doses into arms, galvanize global action, and protect our national security. That is why **we call on President Biden to:**

- **Host a presidential-level "Global Vaccination Summit"** before the UN General Assembly meeting in September; the Summit should bring together public and private sector leaders from around the world, especially from low- and lower-middle income countries, and secure commitments to take the needed actions to close vaccine supply gaps and address financing and capacity gaps in vaccine distribution, delivery, and demand generation;
- **Rally global leaders to commit before or at the Summit to meeting the goal of vaccinating 70 percent of the world's population by mid-2022;** and
- **Launch a US Emergency Plan for Global COVID-19 Relief to help achieve that goal** and augment multilateral efforts, including the COVAX/WHO-coordinated global response and regionally-led efforts such as the Africa Vaccine Acquisition Task Team (AVATT).

The US Emergency Plan for Global COVID-19 Relief should be White House-led, spearheaded by a Global COVID-19 Emergency Response Coordinator reporting to the President and supported by a special inter-agency task force. Its main objectives should be to:

- **Strengthen global coordination of vaccine supply chains and manufacturing.** Greater transparency and accountability in the vaccine marketplace are essential. The US should press for the development of comprehensive monthly estimates of global vaccine input availability (e.g., bioreactors, lipids, filters) and vaccine supply for the coming 12-18 months, so that the US and other countries will have assurances of sufficient doses for future domestic needs, while also maximizing the amount of high-quality vaccines available for global use;

- **Increase US donations to at least 1 billion doses by mid-2022,** including 500 million in 2021, and push other high-income countries to substantially increase donations, so that the US and G7/EU allies collectively donate 1-2 billion doses by the end of 2021;

- **Accelerate globally distributed manufacturing capacity for vaccines and vaccine inputs** by providing financial and technical assistance, and facilitating private sector licensing and knowledge transfer, including for mRNA platform vaccines, to ramp up vaccine manufacturing capabilities in Africa, Latin America, and Asia; and by reaching a global agreement on reducing the use of export restrictions for COVID-19 vaccines, therapeutics, diagnostics, and related inputs; and

- **Most critically, ensure that doses are translated into vaccinations, and strengthen health systems and preparedness for future pandemics,** by accelerating a US-led effort to increase vaccine distribution and delivery capacity, and increase vaccine confidence and demand, in countries with the highest burden of disease, lowest vaccination rates, and least resources, augmenting and complementing multilateral efforts by the development banks, Access to COVID-19 Tools Accelerator and COVAX, Africa Centers for Disease Control, and others.

While these steps can and should be implemented now, they would benefit from additional Congressional support. The administration and Congress should urgently work to advance legislation to fund and sustain a comprehensive international COVID-19 response as well as health systems strengthening and pandemic preparedness efforts.

This plan should be implemented to serve as a catalyst and model for efforts by other high-income nations to use their excess vaccine supplies and technical capabilities to augment the global response. In addition, while focused on the present crisis, this plan should evolve to become part of a permanent initiative to increase preparedness for future pandemics.

This US Emergency Plan for Global COVID-19 Relief reflects both our ideals as a people and our interests as a nation. By galvanizing global efforts to vaccinate the population of the world's poorest, most afflicted countries, it will accelerate the end of the pandemic – here and everywhere.

Please read the full report, *US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security*, to learn more.

Signed By

Center for Global Development | CSIS Center for Strategic & International Studies | COVID Collaborative | Duke Margolis Center for Health Policy; Duke Global Health Innovation Center; Duke Global Health Institute

Amanda Glassman
Executive Vice President, Center for Global Development; CEO of CGD Europe; and Senior Fellow

Rachel Silverman
Policy Fellow, Center for Global Development

Prashant Yadav
Senior Fellow, Center for Global Development

J. Stephen Morrison
Senior Vice President and Director, Global Health Policy Center, CSIS

Katherine Bliss
Senior Fellow, Global Health Policy Center, CSIS

Anna McCaffrey
Fellow, Global Health Policy Center, CSIS

Gary Edson
President, COVID Collaborative

John Bridgeland
CEO, COVID Collaborative

Anjali Balakrishna
Program Director, COVID Collaborative

Mark McClellan
Director, Duke-Margolis Center for Health Policy, Duke University

Krishna Udayakumar
Director, Duke Global Health Innovation Center, Duke University

Michael Merson
Wolfgang Joklik Professor of Global Health, Duke Global Health Institute, Duke University

Endorsed By

Thomas Bollyky
Senior Fellow, Council on Foreign Relations

Scott Gottlieb
Resident Fellow, American Enterprise Institute, and former Commissioner of the US Food and Drug Administration

Carolyn Reynolds
Co-Founder, Pandemic Action Network, and Senior Associate, Global Health Policy Center, CSIS

William Frist
Former U.S. Senator (R-TN) and Former Senate Majority Leader

Margaret (Peggy) Hamburg
Former Commissioner of the US Food and Drug Administration, former Foreign Secretary of the National Academy of Medicine

Helene Gayle
President and Chief Executive Officer, The Chicago Community Trust

Amb [ret] Jimmy Kolker
Former Assistant Secretary, Global Affairs, Department of Health and Human Services

Bruce Gellin
Chief, Global Public Health Strategy, The Rockefeller Foundation

Jack Leslie
Chairman, Weber Shandwick

Following People/NGOs were part of open letter to Biden Administration, 3rd August 2021
Signed by / endorsed by (amongst others): Margret A. (Peggy) Hamburg, Bruce Gellin, Scott Gottlieb, Thomas Bollyky
“US Emergency Plan for Global COVID-19 Relief: Urgent Action to End the Pandemic Globally and Accelerate US Recovery and Security”


Margaret A. Hamburg
CGD - Center for Global Develop...
Member
Signed by Hamburg (FDA?)
Signed
Thomas J. Bollyky was a research fellow at the Center for Global Development from September 2010 to August 2011
CSIS - Center for Strategic and...
Bruce Gellin
SCOTT GOTTLIEB
Thomas J. Bollyky
signed
Signed by
Endorsed (by Gottlibe - FDA?)
Signed By
US Emergency Plan for Global CO...

https://healthpolicy.duke.edu/sites/default/files/2021-08/USEPCR%20Cover%20letter_FINAL_For%20Distribution.pdf

Following People/NGOs were part of open letter to Biden Administration, 3rd August 2021
Signed by / endorsed by (amongst others): Margret A. (Peggy) Hamburg, Bruce Gellin, Scott Gottlieb, Thomas Bollyky
Extended by their relations to Gates Foundation, Wellcome Trust and others.



Connection between BMGF, European Commission, Peter Piot, Emer Cooke (EMA), Heidi Larson (VCP), EFPIA



Sum of GrantsAmountTotal	Column Labels												
Row Labels	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	Grand Total
Albert B. Sabin Vaccine Institute	**7.897.985**	**12.085.497**	**6.071.478**		**18.636.252**	**20.000**	**20.000**	**3.163.373**	**7.435.542**	**641.879**	**1.166.367**	**390.000**	**57.528.373**
Bill & Melinda Gates Foundation	7.897.985	12.085.497	6.071.478		18.636.252	20.000	20.000	3.163.373	7.435.542	641.879	673.577	390.000	57.035.583
GSK											352.600		352.600
Wellcome Trust											140.190		140.190
American Enterprise Institute		**475.536**	**1.262.124**		**1.316.217**	**159.335**	**1.157.579**			**900.000**	**250.000**		**5.520.791**
Bill & Melinda Gates Foundation		445.496	1.068.788		1.316.217	159.335	1.157.579			900.000	250.000		5.297.415
Robert Wood Johnson Foundation		30.040	193.336										223.376
Center for Global Development		**5.763.186**		**5.498.167**	**2.098.745**	**3.503.659**	**7.343.503**	**7.987.488**	**21.429.999**	**5.322.972**	**10.215.198**	**146.002**	**69.308.919**
Bill & Melinda Gates Foundation		5.763.186		5.148.167	914.025	3.503.659	4.343.503	6.187.488	21.380.057	1.164.534	8.415.198		56.819.817
Open Philanthropy				350.000	1.184.720		3.000.000	1.800.000	49.942	4.158.438	1.800.000		12.343.100
Wellcome Trust												146.002	146.002
Center for Strategic and International Studies		**8.145.677**		**1.000.000**		**9.537.181**		**8.074.000**			**3.761.211**		**30.518.069**
Bill & Melinda Gates Foundation		8.145.677		1.000.000		9.537.181		8.074.000			3.398.855		30.155.713
Open Philanthropy											118.307		118.307
Robert Wood Johnson Foundation											244.049		244.049
Charité - Universitätsmedizin Berlin									**549.999**	**1.086.181**	**259.550**		**1.895.730**
Bill & Melinda Gates Foundation									549.999	86.181	249.550		885.730
Wellcome Trust										1.000.000	10.000		1.010.000
Chatham House		**191.935**		**282.631**	**1.095.403**	**356.938**	**146.617**	**136.700**	**434.118**	**116.569**			**2.760.911**
Bill & Melinda Gates Foundation		191.935		282.631	1.095.403	307.288	146.617	136.700	434.118	116.569			2.711.261
Wellcome Trust						49.650							49.650
Coalition for Epidemic Preparedness Innovations (CEPI)							**183.362**	**101.277.016**	**80.680.175**	**4.059.969**	**20.000.000**		**206.200.522**
Bill & Melinda Gates Foundation								100.000.000			20.000.000		120.000.000
Wellcome Trust							183.362	1.277.016	80.680.175	4.059.969			86.200.522
Council on Foreign Relations		**530.000**	**400.000**		**53.100**		**1.000.000**			**183.197**	**700.294**	**698.403**	**3.564.994**
Bill & Melinda Gates Foundation		530.000	400.000				1.000.000			183.197	700.294	698.403	3.511.894
Robert Wood Johnson Foundation					53.100								53.100
European Commission							**500.000**			**45.178.000**	**500.000**		**46.178.000**
Bill & Melinda Gates Foundation							500.000			45.178.000	500.000		46.178.000
London School of Hygiene & Tropical Medicine	**32.242.822**	**35.296.421**	**18.183.902**	**28.592.802**	**23.075.855**	**34.897.169**	**28.408.827**	**68.092.466**	**32.161.719**	**21.726.570**	**21.000.078**	**9.823.615**	**353.502.246**
Bill & Melinda Gates Foundation	21.601.425	18.672.120	1.836.336	13.123.576	10.448.820	22.056.301	14.478.175	39.982.036	19.408.074	16.359.406	7.362.722		185.328.991
Wellcome Trust	10.641.397	16.624.301	16.347.566	15.469.226	12.627.035	12.840.868	13.930.652	28.110.430	12.753.645	5.367.164	13.637.356	9.823.615	168.173.255
Nuclear Threat Initiative								**6.726.859**	**5.461.715**		**9.500.045**		**21.688.619**
Bill & Melinda Gates Foundation								250.000			1.000.045		1.250.045
Open Philanthropy								6.476.859	5.461.715		8.500.000		20.438.574
Pfizer			**96.462**				**17.252.854**						**17.349.316**
Bill & Melinda Gates Foundation							17.252.854						17.252.854
Wellcome Trust			96.462										96.462
Robert Koch Institut								**38.317**		**253.000**			**291.317**
Bill & Melinda Gates Foundation										253.000			253.000
Wellcome Trust								38.317					38.317
World Health Organization	**44.012.053**	**72.270.654**	**200.885.383**	**399.386.075**	**645.774.522**	**197.178.706**	**118.061.247**	**234.127.556**	**284.599.026**	**217.274.610**	**298.952.191**	**112.880.895**	**2.825.402.918**
Bill & Melinda Gates Foundation	44.012.053	71.993.007	200.885.383	399.366.566	642.616.767	195.112.242	117.048.753	234.086.580	277.644.327	213.837.542	296.027.811	99.743.257	2.792.374.288
Robert Wood Johnson Foundation							448.830		429.829	451.543			1.330.202
Wellcome Trust		277.647		19.509	3.157.755	2.066.464	563.664	40.976	6.524.870	2.985.525	2.924.380	13.137.638	31.698.428
Grand Total	**84.152.860**	**134.758.906**	**226.899.349**	**434.759.675**	**692.050.094**	**245.652.988**	**174.073.989**	**429.623.775**	**432.752.293**	**296.742.947**	**366.304.934**	**123.938.915**	**3.641.710.725**

Media

AFP


BMGF - Bill & Melinda Gates Fou...
Financed 45 MioS
Financed
FinancedClient of
AFP
European Commission
UNFPA - United Nations Populati...
unicef
Roche Group
BBC
CNN
Client of
Client of
Client of
Client of
Client of
Client of
AFP Factstory - P&R Agent
AFP Factcheck
Part of
Fact-checking on Facebook

Luminate + Child Objects 1 Level connection



https://firstdraftnews.org



Misc

BanQu Inc.
Investor of Change.org

Change.org

‹ Back
THE WORLD ECONOMIC FORUM | FEBRUARY 16, 2021

BanQu is in The Circulars Accelerator 2021 Cohort

[BanQu Inc. :: Minnesota (US) :: OpenCorporates]

BanQu Inc. BRANCH

Company Number	a372c8f0-1fd4-e511-8164-00155d01c56d
Native Company Number	873011800028
Status	Active
Incorporation Date	15 February 2016 (over 5 years ago)
Company Type	Business Corporation (Foreign)
Jurisdiction	Minnesota (US)
Branch	Branch of BANQU, INC. (Delaware (US))
Registered Address	1010 Dale St N St Paul 55117-5603 MN USA
Governing Legislation	303
Agent Name	National Registered Agents, Inc

[642 Simon Ave - Google Maps]

Abbott Diabetes Care Sales Corporation

BRANCH

Company Number	b96428df-8dd4-e011-a886-001ec94ffe7f
Native Company Number	1899138-3
Status	Active
Incorporation Date	16 June 2006 (almost 15 years ago)
Company Type	Business Corporation (Foreign)
Jurisdiction	Minnesota (US)
Branch	Branch of ABBOTT DIABETES CARE SALES CORPORATION (Delaware (US))
Registered Address	1010 Dale St N St Paul 55117-5603 MN USA
Governing Legislation	303
Agent Name	C T Corporation System Inc
Directors / Officers	C T Corporation System Inc, agent Jared Watkin, chief executive officer
Registry Page	https://mblsportal.sos.state.mn.us/Bu...

[Abbott Diabetes Care Sales Corporation :: Minnesota (US) :: OpenCorporates]

[Company officers with names matching 'C T Corporation System Inc' :: Page 1 :: OpenCorporates]

C T Coporation has several hundred branches of various companies registered here. Interesting: There are some pharmaceutical companies registered here. C T Corporation is a part of Walter Kluwer Group.

ROADMAP FOR THE IMPLEMENTATION OF ACTIONS BY THE EUROPEAN COMMISSION BASED ON THE COMMISSION COMMUNICATION AND THE COUNCIL RECOMMENDATION ON STRENGTHENING COOPERATION AGAINST VACCINE PREVENTABLE DISEASES


ACTIONS
TIMELINES AND DELIVERABLES
2018
2019
2020
2021
2022
Examine the feasibility of developing a common vaccination card/passport for EU citizens (that takes into account potentially different national vaccination schedules and), that is compatible with electronic immunisation information systems and recognised for use across borders, without duplicating work at national level.
CR 16 and CC*
Feasibility study for the development of a common EU vaccination card
Commission proposal for a common vaccination card/ passport for EU citizens
State of Vaccine Confidence in the EU 2020
Follow up of the study published in October 2018
https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf
Guidance on countering vaccine hesitancy tailored to specific needs identified by the Member States and/ or vaccine specific issues
Produce on a regular basis a Report on the State of Vaccine Confidence in the EU, to monitor attitudes to vaccination. Based on that report and taking into account related work by WHO, present guidance that can support Member States in countering vaccine hesitancy.
Special Eurobarometer - Europeans' attitudes towards vaccination
https://ec.europa.eu/commfrontoffice/publicopinion/index.cfm/survey/getsurveydetail/instruments/special/surveyky/2223
CR 17 and CC

*** Basis for action:**
CR for Council Recommendation and the number of the Recommendation in the legal text. CC for Commission Communication

https://ec.europa.eu/health/sites/health/files/vaccination/docs/2019-2022_roadmap_en.pdf

“Selected Person”

Chris (Christopher) Elias



Lothar H. Wieler



Margret A. Hamburg



Christian Drosten



Scott Gottlieb


SCOTT GOTTLIEB
Board Member
Pfizer
Author
Co-Author
American Enterprise Institute Washington D.C. Metro Area from 2003 to Present Senior Fellow
Advisory Board
Dr. Gottlieb served as the 23rd Commissioner of the U.S. Food and Drug Administration (FDA) from 2017 to 2019
Endorsed (by Gottlibe - FDA?)
FDA
Health Costs And Financing: Cha...
Investment Partner
Board of Directors
American Enterprise Institute
Tempus
Illumina
US Emergency Plan for Global CO...
Member of the Product Investment Board at GlaxoSmithKline from January 2010 to April 2017
Published
NEA - New Enterprise Associates
GsK GlaxoSmithKline
Different Articles published by...

Anthony Fauci



Ralph S. Baric


Ralph S. Baric
Dissertation Committee Member - See CV Ralph Baric
Kizzmekia S. Corbett
Inventor
Dr. Heise is a founding member, along with Drs. Ralph Baric and Nathaniel Moorma...
Former Postdoctoral Fellows -see CV Ralph Baric
Author
Speaker
Inventor
Member
Patent USUS20110070262A1 - UL...
Patent US8318802 - Compositions...
US10407810 - Characterization...
Patent US9884895B2 - METHODS A...
Patent US7279327 B2 - METHODS A...
Academies of Sciences...
Middle East Respiratory Syndrom...
YouTube: Imagining the Next Pan...
Feasibility for reverse zoonoti...
Patent US 6593111B2 - DIRECTION...
READDI - Rapidly Emerging Antiv...
2014-12-24 - Gain of Function S...
CV Ralph Baric
Rachel Graham
Author
ASSISTANT PROFESSOR DEPARTMENT OF EPIDEMIOLOGY
Die Materialtransfervereinbarung wurde am 12. Dezember 2019 von Ralph Baric, PhD, und am 16. Dezember 2019 von Jacqueline Quay – beide von der University of North Carolina – unterzeichnet.
U19 AI100625 Systems Immunogenic...
Publications
The University of North Carolin...
Leaked NDA Moderna / NIAD

Jeremy Farrar


Jeremy Farrar
PPP Steering Group member
Author
Initiative Members Unable to Attend Kick-Off
Wellcome Trust
WHO - World Health Organization
2021-01-12/32 Some Future Fauci Leaked E-Mails
UK - Pandemic Preparedness Part...
NTI - 2019-02-14 - Tabletop Exercise
Statement in support of the sci...
With initial funding of £250 million furnished by the Wellcome Trust
belongs to
CDU / CSU - Globale Gesundheit ...
NTI - 2018-10-29 - Biosecurity...
NTI - 2018-07-20/21 - Construct...
UK
Wellcome Leap
GPMB
WHO R&D Blueprint

Rajiv Shah


BMGF - Bill & Melinda Gates Fou...
Financed
Shah joined the Bill & Melinda Gates Foundation in 2001, serving in a range of leadership roles including Direct
is working for (as Managing Director, Global Policy & Advocacy, Bill & Melinda Gates Foundation)
Finance
Financed
Joe Cerrell
YGL - Young Global Leaders
FB Friend
Rajiv Shah
Member of NORTH AMERICAN GROUP
President
Board of Advisors
Board Member
worked for in different positions
IRC - International Rescue Comm...
The Rockefeller Foundation
Atlantic Council
The Trilateral Commission
USAID
COLLABORATING INSTITUTIONS
Team Member
COVID Collaborative

Matthew Hepburn


White House
Former Director of Medical Preparedness on the White House National Security Staff
2021-01-12/32 Some Future forum...
Speaker
Matthew Hepburn
Program Manager since (2013-2019)
DARPA
Expert Contributors
Former Joint Project Lead, Enabling Biotechnologies for the JPEO CBRND defense
Vaccine Lead for Operational Warp Speed
Operational Warp Speed
JPEO-CBRND -The Joint Program E...
NTI - Expert Contributors to Sc...

Sharyl Sandberg



Peter Piot


BMGF - Bill & Melinda Gates Fou...
Grants
Finance
Finance
Partnership
Partner of WEF
Grants 185 Mio USD (since 2010)
The Potential Future of the COV...
IHME - The Institute for Health...
IHME Partner of Exemplars
Exemplars Health
UNAIDS - United Nations Joint A...
Director of European Initiatives at the Institute for Health Metrics and Evaluation (IHME)
Former Executive Director of UNAIDS and Under Secretary-General of the United Nations
Leopoldina
RKI Robert Koch Institut - Scie...
Author
Mitglied
Chair
Member
Peter Piot
Board Member
Commission's advisory panel on ...
Novartis Foundation
Voting Member
Author
Director
Board Member Chair
London School of Hygiene & Tropical Medicine
The King Baudouin Foundation Un...
Married
EXTERNAL ADVISORY BOARD
Married
WEF - World Economic Forum
Heidi Larson
London School of Hygiene & Trop...
CEPI was formally launched at the 2017 WEF in Davos
Clinical Associate Professor
founded in 2010 by Heidi Larson
VCP - Vaccine Confidence Project
CEPI Coalition for Epidemic Pre...
University of Washington - Depa...

Heidi Larson



Emer Cooke


Executive Director
Emer Cooke
EMA - European Medicines Agency
From 1991 to 1998 Emer Cooke was a board member of the EFPIA
Head of Regulation of Medicines and other Health Technologies
EFPIA
WHO - World Health Organization

Georg F. Gao


China CDC - Chinese Center for ...
China
Director-General
President
Chinese Society of Biotechnolog...
CEPI 2021-2024 Scientific Advisory Committee Members
Board Member
Board Member GPMB
Board Member
GPMB
CEPI Coalition for Epidemic Pre...
Donor
FIND
FIND
Dean, Medical School, University of Chinese Academy of Sciences
Georg F Gao
University of Chinese Academy o...
Player
Event 201
Speaker
Executive Board
2021-01-12/32 Some Future forum...
Author
President
IANPHI - The International Asso...
Contributor
Foreign associate of the US National Academy of Sciences, 2019
Member
Academician of the International Eurasian Academy of Sciences, 2018
Vice President
NAM - National Academy of Medic...
NAS - National Academy of Scien...
Document - The Global Virome Pr...
Leopoldina
Asian Federation of Biotechnolo...
NSFC - National Natural Science...
Laboratory testing of 2019 nove...

Ilona Kickbusch



Tim Evans


Event 201
Player
Tim Evans
PARTICIPANT
NTI - 2018-07-20/21 - Construct...
Former Senior Director of the Health, Nutrition and Population Global Practice
worked for
worked for
founder
Attendee
Speaker
contribute to
worked for
McGill University
worked for
contribute to
World Bank
INDEPTH
Founding Partner
contribute to
NTI - 2019-02-14 - Tabletop Exe...
NTI - 2019-05-29 - bio Focuses ...
The Rockefeller Foundation
World Bank Blog
WHO - World Health Organization
Health Metrics networks, die GI...
Funding
belongs to WHO
Founding Partner
Harvard School of Public Health
GAVI
World Alliance for Patient Safe...

Matthew Hepburn


White House
Former Director of Medical Preparedness on the White House National Security Staff
2021-01-12/32 Some Future forum...
Speaker
Matthew Hepburn
Vaccine Lead for Operational Warp Speed
Operational Warp Speed
Expert Contributors
Program Manager since (2013-2019)
Former Joint Project Lead, Enabling Biotechnologies for the JPEO CBRND defense
NTI - Expert Contributors to Sc...
DARPA
DARPA
JPEO-CBRND -The Joint Program E...

Julie Louse Gerberding


JULIE LOUISE GERBERDING
CO-CHAIRS
CSIS - Center for Strategic and...
Board of Directors
Served as Director of the U.S. Centers for Disease Control and Prevention (CDC) from 2002 to 2009.
Player
Board of Directors
Executive Vice President and Chief Patient Officer at Merck
Clade-X
CDC - Centers for Disease Contr...
Cerner Corporation
MSD / Merck
Jjoint-venture Merkc & Wellcome Trust
Hilleman Laboratories

Peter Daszak



Joe Cerrell


BMGF - Bill & Melinda Gates Fou...
Finance
Joe Cerrell
FB Friend
Speaker
Peter A Singer
APCO Worldwide
Steven VanRoekel
CDU / CSU - Globale Gesundheit
Global Citizen
Save the Children
Rajiv Shah
friend
Seth Berkley
Sheryl Sandberg
Jamie Drummond
ONE
ONE

Richard Danzig



Beth Cameron


Beth Cameron
Speaker
e State Department and in the health policy office of Senator Edward M. Kennedy where she worked on the Patients' Bill of Rights, medical privacy, and legislation to improve the quality of cancer care
Team Member
Attendee
Beth Cameron was formerly NTI's vice president for global biological policy and program
Project Team
Contributors
NTI - Nuclear Threat Initiative
AAAS - American Association for...
Wilton Park - 2018-11-07/8/9 - ...
COLLABORATING INSTITUTIONS
Published by WEF / NTI
Host
NTI - 2019-05-29 - bio Focuses ...
COVID Collaborative
NTI - 2019-02-14 - Tabletop Exe...
Biosecurity Innovation and Risk...
NTI - 2018-10-29 - Biosecurity ...

Avril Haines



Amelia Fawcett



Muhammed Pate



Victor Dzau


2021-01-12/32 Some Future forum...
Speaker
Victor Dzau
President
The National Academy of Medicine
he serves as Vice Chair
Board Member GPMB
Board Member
IHME Board
President of the
US National Research Council
COUNCIL CO-CHAIRS
President
GPMB
WEF - World Economic Forum
USA
IHME - The Institute for Health...
NAM - National Academy of Medic...
US National Academy of Medicine
WEF - Global Future Council on ...

Richard Hatchett


BARDA - Biomedical Advanced Res...
Former Director of BARDA
Richard Hatchett
Initiative Members Unable to Attend Kick-Off
Participant
NTI - 2018-10-29 - Biosecurity ...
Chief Executive Officer
https://blogs.worldbank.org/team/richard-j-hatchett
PPP Steering Group member
NTI - 2020-02-xx - 2020 Munich ...
UK - Pandemic Preparedness Part...
World Bank Blog
CEPI Coalition for Epidemic Pre...

Elhadj As Sy


Red Crescent Societies
Former Secretary General of the International Federation ofthe Red Cross and Red Crescent Societies
Participant
Elhadj As Sy
Former Secretary General of the International Federation ofthe Red Cross and Red Crescent Societies
Attendee
NTI - 2020-02-xx - 2020 Munich ...
Co-Chair
Board of Governors
Red Cross
GPMB
Wellcome Trust
NTI - 2019-02-14 - Tabletop Exe...

John Nkengasong


John Nkengasong
Director
eputy principal director (acting) of the Center for Global Health, United States Centers for Disease Control and Prevention (U.S. CDC)
Bio Advisory Group
Board Member
Speaker
Africa Centres for Disease Cont...
He serves on several international advisory boards including IAVI
IAVI
NTI - Nuclear Threat Initiative
RKI Robert Koch Institut - Scie...
He serves on several international advisory boards including the Coalition for Epidemic Preparedness Initiative – CEPI
CDC - Centers for Disease Contr...
2021-01-12/32 Some Future forum...